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1. INTRODUCTION 
1.1. Introduction to Analytical Chemistry  
                                                   (www.en.wikipedia.org/wiki/Analytical_chemistry) 
Analytical chemistry is the study of the separation, identification, and 
quantification of the chemical components of natural and artificial materials. 
Qualitative analysis gives an indication of the identity of the chemical species in the 
sample and quantitative analysis determines the amount of one or more of these 
components. The separation of components is often performed prior to analysis. 
1.2 Ultra Violet Spectroscopy         (Beckett A.H and stenlake J.B., 2002) 
Ultraviolet spectroscopy deals with the measurement of energy absorbed when 
electrons are promoted to higher energy state. On passing electromagnetic radiation in 
the ultraviolet and visible regions through the compound with multiple bonds, a 
portion of the radiation is normally absorbed by the compound. The amount of 
absorption depends on the wavelength of the radiation and the structure of the 
compound. Absorption of the electromagnetic radiation in the visible and ultraviolet 
region of spectrum results in changes of electronic structure of ions and molecules. 
1.2.1. Beer’s law  
 The intensity of a beam of monochromatic light decreases exponentially with 
the increase in concentration of the absorbing substance arithmetically. 
I = I0e-kc 
Where,  I0 = intensity of incident light 
 I = Intensity of emerged light 
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1.2.2. Lambert’s law 
 When a beam of light of light is allowed to pass through a transparent medium, 
the rate of decrease in the intensity of transmitted light with the thickness of medium 
is directly proportional to the intensity of the incident light. 
 
From these laws, the following empirical expression – Beer and Lambert’s Law 
A= Єct 
Where,  A= Absorbance or optical density or extinction co-efficient 
 Є = Molecular extinction co-efficient 
  c = Concentration of drug  
  t = Path length 
1.3.   Quantitative spectrophotometric assay of medicinal substances 
           The assay of an absorbing substance may be quickly carried out by preparing a 
solution in a transparent solvent and measuring its absorbance at a suitable 
wavelength. The wavelength normally selected is a wavelength of maximum 
absorbance (λmax) where small errors in setting the wavelength scale have little effect 
on the measured absorbance.  Ideally, the concentration should be adjusted to give an 
absorbance of approximately 0.9, around which the accuracy and precision of the 
measurement are optimal. The preferred method is to read the absorbance from the 
instrument display under non-scanning conditions, i.e. with the monochromator set at 
the analytical wavelength. Alternatively, the absorbance may be read from a 
recording of the spectrum obtained by using a recording double-beam 
spectrophotometer. The concentration of the absorbing substance is then calculated 
from the measured absorbance using one of three principal procedures.  
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1.3.1. Use of Standard Absorptivity value 
 Absorptivity value A (1%1cm) or € avoids the need of standard solution of 
reference substance. It is advantageous where it is difficult or expensive to get pure 
sample of reference substance. 
1.3.2. Use of a Calibration graph 
           In this procedure the absorbance’s of a number of standard solutions of the 
reference substance at concentration in compassing the sample concentrations are 
measured and a calibration graph is constructed. The concentration of the sample 
solution is read from the graph as the concentration corresponding to the absorbance 
of the solution. Calibration data are essential if the absorbance has a non-linear 
relationship with concentration, if it is necessary to confirm the proportionality of 
absorbance as a function of concentration or if the absorbance or linearity is 
dependent on the assay conditions.  
 If the absorbance values and concentrations correlate a linear relationship, the 
regression line y=αx+β may be estimated by the method of squares. 
( )( ) ( )( )
( )22
2
xxN
xyxxy
α
∑∑
∑∑∑∑
−
−
=  
( )( )
( )22 xxN
yxxyN
β
∑∑
∑∑∑
−
−
=  
Where,   α  = Intercept 
   β  = Inter slope 
                        x  =         concentration  
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                        Y          = absorbance 
                        N          = number of pairs of values. 
InterslopeAvg
InterceptAvgyionConcentrat
.
.−
=
 
1.3.3. Methods carried out 
i. Geometric Correction Method  
ii. Derivative Spectroscopic Method 
iii. Colorimetric Method 
1.3.3.1Geometric correction method 
A number of mathematical correction procedures have been developed which 
reduce or eliminate the background irrelevant absorption that may be present in 
samples of biological origin. The simplest of these procedures is the three-point 
geometric procedure, which may be applied if the irrelevant absorption is linear at the 
three wavelengths selected. Consider an absorption spectrum (Fig .a) comprising the 
spectrum of analyte (Fig .b) and that of the background absorption (Fig. c). If the 
wavelengths λ1, λ2 and λ3 are selected so that the background absorbance’s B1, B2, and 
B3 are linear, then the corrected absorbance, D, of the drug may be calculated from the 
three absorbance’s A1, A2, and A3 of the sample solution at λ1, λ2 and λ3 respectively, 
as follows. 
Let vD and wD be the absorbance of the drug alone in the sample solution at λ1 
and λ3 respectively, i.e. v and w are the absorbance ratios vD/D and wD/D 
respectively. 
                      Therefore B1 = A1-vD, B2 = A2-D and B3 = A3-wD 
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Let y and z be the wavelength intervals (λ2-λ1) and (λ3-λ2) respectively. 
Then 
 =  (similar triangles) 
                          Therefore zB1 = (y + z) B2-yB3 
                            Z (A1 - vD) = (y + z) (A2 - D)-y(A3 –v D) 
Rearranging:  
D =  
This is general equation which may be applied in any situation where A1, A2 
and A3 of the sample, the wavelength intervals y and z and the absorbance ratios v and 
w are known. The values of v and w are determined experimentally using a solution of 
drug only. The concentration of the drug is calculated from the corrected absorbance 
D using any of the normal procedures. 
Two special circumstances allow further simplification of the general equation. 
Firstly, when the wavelengths λ1, λ2 and λ3 are selected to give v=w=r, the general 
equation simplifies to: 
D =  
It should be noted that the three-point correction procedures are simply 
algebraic calculations of what the baseline technique in infrared spectrophotometry 
does graphically. 
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Fig. (a)The absorption spectrum of a solution of a drug in the presence of 
linear irrelevant absorption 
 
Fig. (b)The individual spectrum of the drug 
 
Fig. (C)The individual spectrum of the linear irrelevant absorption 
1.3.3.2. Derivative Spectrophotometry 
Derivative spectrophotometry involves the conversion of a normal spectrum to 
its first, second or higher derivative spectrum. The transformations that occur in the 
derivative spectra are understood by reference to a Gaussian band which represents an 
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ideal absorption band. In the context of derivative spectrophotometry, the normal 
absorption spectrum is referred to as the fundamental, zeroth order or D° spectrum. 
The first derivative (D1) spectrum is a plot of the ratio of change of absorbance 
with wavelength against wavelength, i.e. a plot of the slope of the fundamental 
spectrum against wavelength or a plot of dA/dλ Vs λ. At λ2 and λ4, the maximum 
positive and maximum negative slope respectively in the D°. Spectrums correspond 
with maximum and a minimum respectively in the D1 spectrum. The λmax at λ3 is a 
wavelength of zero slopes and gives dA/d λ 0, i.e. a cross-over point, in the D1 
spectrum.  
The second derivative (D2) spectrum is a plot of the curvature of the D° 
spectrum against wavelength or a plot of d2A/dλ2Vs λ. The maximum negative 
curvature at λ3 in the D° spectrum gives a minimum in the D2 spectrum, and at λ1 and 
λ5 the maximum positive curvature in the D° spectrum gives two small maxima called 
‘satellite’ bands in the D2 spectrum. At λ2 and λ4 the 
 
The zeroth (a), first (b) and second (c) derivative spectra of a Gaussian band. 
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Wavelengths of maximum slope and zero curvature in the D° spectrum 
correspond with cross-over points in the D2 spectrum. 
In summary, the first derivative spectrum of an absorption band is 
characterized by a maximum, a minimum, and a cross-over point at the λmax of the 
absorption band. The-second derivative spectrum is characterized by two satellite 
maxima and an inverted band of which the minimum corresponds to the λmax of the 
fundamental band.  
These spectral transformations confer two principal advantages on derivative 
spectrophotometry. Firstly, an even order spectrum is of narrower spectral bandwidth 
than its fundamental spectrum. Secondly, derivative spectrophotometry discriminates 
in favour of substances of narrow spectral bandwidth against broad bandwidth 
substances. This is because ‘the derivative amplitude (D), i.e. the distance from a 
maximum to a minimum, is inversely proportional to the fundamental spectral 
bandwidth (14’) raised to the power (n) of the derivative order. Thus,               
D α (1/W)n 
Consequently, substances of narrow spectral bandwidth display larger derivative 
amplitudes than those of broad bandwidth substance 
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(a) The individual spectra of two components X and Y in admixture and their 
combined spectrum.  
(b) The second derivative spectrum of the mixture showing improved 
resolution of the individual bands. 
The enhanced resolution and bandwidth discrimination increases with 
increasing derivative order. However, it is also found that the concomitant increase in 
electronic noise. Inherent in the generation of the higher order spectra, the consequent 
reduction of the signal-to-noise ratio, place serious practical limitations on the higher 
order spectra. 
1.3.3.3 Visible Spectrophotometry                                         (B.K. Sharma, 2006) 
Visible spectrophotometry involves the measurement of the amount of visible 
radiation (400 - 800 nm) absorbed by a colour solution. Using this, the quality of an 
element present is estimated from the intensity of the colour of the solution due to the 
presence of a coloured compound of that element. The more intense colour is the 
higher concentration of the element in solution. Some compounds are self coloured 
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and for other it is necessary to develop colour by the addition of one or more colour 
forming reagents (chromogenic reagents). The absorbing capacity of a coloured 
system is directly proportional to the amount of desired constituent. 
Colorimetric analysis should satisfy following criteria. 
 The colour reaction should be specific 
 Proportionality change between colour and concentration 
 Colour should be stable to permit an accurate reading 
 Reproducible result should be notified 
 Solution must be free from precipitate 
 The colour reaction should be highly sensitive 
1.4. Chromatography                                   (Gary D. Christian, 2005)  
Chromatography is a physical method of separation in which the components 
to be separated are distributed between two phases, one of which is stationary 
(stationary phase), while the other (the mobile phase) moves in a definite direction. 
Chromatography was invented and named by the Russian Botanist Mikhail Tswett at 
the beginning of the 20th Century. 
1.4.1 High-Performance Liquid Chromatography (HPLC) 
(http://www.files.chem.vt.edu/chem-ed/sep/lc/hplc.htmL) 
Introduction 
High-performance liquid chromatography (HPLC) is a form of liquid 
chromatography to separate compounds that are dissolved in solution. HPLC 
instruments consist of a reservoir of mobile phase, a pump, an injector, a separation 
column, and a detector. Compounds are separated by injecting a plug of the sample 
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mixture onto the column. The different components in the mixture pass through the 
column at different rates due to differences in their partitioning behavior between the 
mobile liquid phase and the stationary phase. 
Reverse-phase partition chromatography uses a relatively nonpolar stationary phase 
and a polar mobile phase, such as methanol, acetonitrile, water, or mixtures of these 
solvents. The most common bonded phases are n-octyldecyl (C18) and n-decyl (C8) 
chains, and phenyl groups. Reverse-phase chromatography is the most common form 
of liquid chromatography, primarily due to the wide range on analytes that can 
dissolve in the mobile phase. 
Normal-phase partition chromatography uses a polar stationary phase and a nonpolar 
organic solvent, such as n-hexane, methylene chloride, or chloroform, as the mobile 
phase. The stationary phase is a bonded siloxane with a polar functional group. The 
most common functional groups in order of increasing polarity are: 
cyano: -C2H4CN 
diol: -C3H6OCH2CHOHCH2OH 
amino: -C3H6NH2 
dimethylamino: -C3H6N(CH3)2 
 
Adsorption Chromatography 
The stationary phases in adsorption chromatography are silica or alumina 
particles. Analytes are separated due to their varying degree of adsorption onto the 
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solid surfaces. The main advantage of adsorption chromatography is in separating 
isomers, which can have very different physisorption characteristics due to steric 
effects in the molecules. 
1.4.2. Summary of HPLC operation                                                      
1. Filter and degas mobile phase. 
2. Prime pump, rinse column with strong solvents and equilibrate column. 
3. Purge injection and make sure there are no air bubbles in the sample syringe. 
4. Perform system suitability test. 
5. Analyze sample. 
6. Process and report data. 
7. Rinse column and shut down pump and lamps. 
1.4.3. HPLC method development                                             (Lloyd et al., 1997) 
The wide variety of equipment, columns, eluent and operational parameters 
involved makes high performance liquid chromatography (HPLC) method 
development seem complex. The process is influenced by the nature of the analytes. 
The different stages in method development was given in the following flow chart 
Selection of the HPLC method and initial system 
 
                                              Selection of initial conditions 
 
                                              Selectivity optimization 
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                                                System optimization 
 
                                                Method validation 
1.5 Analytical Method Validation 
(Code Q2A; Q2B. ICH Guidelines1994 and 1996) 
Method validation is the process to confirm that the analytical procedure 
employed for a specific test is suitable for its intended use. Methods need to be 
validated or revalidated. The International Conference of Harmonization (ICH) of 
technical requirements for the registration of pharmaceutical for human use has 
developed a consensus text on validation of analytical procedures. The document 
includes definition for eight validation characteristics. 
The parameters as defined by the ICH and by other organizations 
 Specificity  
 Selectivity 
 Precision  
 Repeatability  
 Intermediate precision  
 Reproducibility  
 Accuracy  
 Linearity  
 Range  
 Limit of detection  
 Limit of quantification  
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 Robustness  
 Ruggedness  
1.5.1 Specificity  
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to present. An investigation of specificity should 
be conducted during the validation of identification tests, the determination of 
impurities and assay. 
1.5.2 Accuracy  
  The accuracy of an analytical procedure expresses the closeness of 
agreement between the value which is accepted either as a conventional true value or 
on an accepted reference value and the value found.  
1.5.2.1 Assay  
- Assay of Active substances 
- Assay of Medicinal products  
 Several methods are available to determine the accuracy   
a) Application of an analytical procedure to an analyte of known purity  
b) Comparison of the results of the proposed analytical procedure 
c) Application of the analytical procedure to synthetic mixtures 
1.5.2.2 Impurity (Quantification) 
Accuracy should be assessed on sample spiked with known amounts of             
impurities. It should be clear how the individual or total impurities are to be                 
determined. 
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Eg: weight/weight or area percent 
1.5.3 Precision  
The precision of an analytical procedure expresses the closeness of the     
agreement between a series of measurements obtained from multiple sampling of 
same homogeneous sample under the prescribed conditions. Validation of tests for 
assay and for quantitative determination of impurities includes an investigation of 
precision. 
1.5.3.1 Repeatability (intra- assay precision) 
Express the precision under small operating conditions over a short interval of 
time. It should be assessed using a minimum of nine determinations. 
1.5.3.2 Intermediate Precision 
The extent to which intermediate precision should be established depends on 
the circumstances under which the procedure is intended to be used. Typical 
validation to be studied includes days, analysts, equipments, etc. 
1.5.3.3 Reproducibility 
Reproducibility is assessed by means of an inter-laboratory trail.                    
Reproducibility should be considered in case of the standardization of an analytical 
procedure, for insistence inclusion of procedure in pharmacopoeias.  
1.5.4 Linearity 
 Linearity of an analytical procedure is its ability (with in a given range) to 
obtain test results which are directly proportional to the concentration (amount) of 
analyte sample. 
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1.5.5 Range 
Range of an analytical procedure is the interval between the upper and lower 
concentration of analyte in the sample including these concentrations for which it has 
been demonstrated that the analytical procedure has a suitable level of precision, 
accuracy and linearity. 
1.5.6 Limit of Detection  
The detection limit is determined by the analysis of samples with known             
concentration of analyte and by establishing that minimum level at which the analyte 
can reliably detected. 
a. Based on visual evaluation 
b. Based on Signal-to-Noise ratio 
c.  Based on the standard deviation of the response and the slope 
• Based on the standard deviation of blank 
• Based on the calibration graph 
1.5.7 Limit of Quantification  
The quantification limit is generally determined by the analysis of samples 
with the known concentrations of analyte and by establishing the minimum value at 
which the analyte can be quantified with acceptable accuracy and precision 
a. Based on visual evaluation  
b. Based on Signal-to- Noise ratio 
c. Based on the standard deviation of the response and the slope 
• Based on the standard deviation of blank 
• Based on the calibration graph 
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1.5.8 Robustness 
 The evaluation of robustness should be considered during the development 
phase and depends on the type of procedure under study. It shows the reliability of an 
analysis with respect to deliberate variations in the method parameters. 
1.5.9 Ruggedness 
 The united states of pharmacopoeia (USP) define ruggedness as the degree of 
reproducibility of test results obtained by the analysis of the same sample under a 
variety of normal test condition such as different labs, different analysis, different lots 
of reagents etc. Ruggedness is a measure of reproducibility of test results under 
normal expected operational conditions from laboratory to laboratory and from analyst 
to analyst. 
1.6.1. System Suitability Parameters         (Lloyd, 1997; Beckett and Stenlake, 2007) 
System suitability testing is an integral part of many analytical procedures. The 
tests are based on the concept that the equipment, electronics, analytical operations, 
and samples to be analyzed constitute an integral system that can be evaluated as such. 
System suitability test parameters to be established for a particular procedure depend 
on the type of procedure being validated.  
The parameters that are affected by the changes in chromatographic conditions 
are, 
• Column capacity factor (KA) 
• Resolution (Rs) 
• Selectivity (α) 
• Column efficiency (N) and 
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• Peak asymmetry factor (As) 
• Tailing factor (T) 
1.6.1.1. Column capacity factor (KA) 
The retention of a drug with a given packing material and eluent can be 
expressed as retention time or retention volume, but both of these are dependent on 
flow rate, column length and column diameter. The retention is best described as a 
column capacity ratio (K), which is independent of these factors. The column capacity 
ratio of a compound (A) is defined as  
0
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where, 
VA = Elution volume of A 
V0 = Elution volume of a non retained compound (void volume) 
At constant flow rate, retention times (tA and to) can be used instead of 
retention volumes. Retention data is sometimes expressed, relative to a known internal 
standard (B). The ratio of retention times (tA/tB) can be used, but the ratio of adjusted 
retention times  

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 is better when data need to be transferred between 
different chromatographs. 
The values of ‘k’ of individual bands are increase or decrease with changes in 
solvent strength. In reversed phase HPLC, solvent strength increases with the increase 
in the volume of organic phase in the water / organic mobile phase. Typically an 
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increase in percentage of the organic phase by 10 % by volume will decrease k’ of the 
bands by a factor of 2-3.  
 
1.6.1.2 Resolution (Rs) 
The resolution, Rs of two neighboring peaks is defined by the ratio of the 
distance between the two peak maxima. It is the difference between the retention 
times of two solutes divided by their average peak width. For baseline separation, the 
ideal value of Rs is 2.0. It is calculated by using the formula, 
)WW(5.0
RtRt
R
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where,  
Rt1 and Rt2 are the retention times of components 1 and 2  
W1 and W2 are peak widths of components 1 and 2. 
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1.6.1.3. Selectivity (α) 
The selectivity (or separation factor), α, is a measure of relative retention of 
two components in a mixture. The ideal value of selectivity is 2. It can be calculated 
by using the formula,   
01
02
VV
VV
−
−
=α
 
Where, V0 is the void volume of the column and V2 and V1 are the retention    
volumes of the second and the first peak, respectively. 
 
1.6.1.4. Column efficiency 
Efficiency, N, of a column is measured by the number of theoretical plates per 
meter. It is a measure of band spreading of a peak. Smaller the band spread, higher is 
the number of theoretical plates, indicating good column and system performance. 
Columns with N ranging from 5,000 to 100,000 plates/meter are ideal for a good 
system. Efficiency is calculated by using the formula, 
2
2
16
W
RtN =  
Where, 
Rt is the retention time and W is the peak width. 
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1.6.1.5. Peak asymmetry factor (As) 
Peak asymmetry factor, As can be used as a criterion of column performance. 
The peak half width b of a peak at 10 % of the peak height, divided by the 
corresponding front half width a gives the asymmetry factor. 
a
bAS =  
1.6.1.6. Tailing factor (T) 
The tailing factor T, a measure of peak symmetry, is unity for perfectly 
symmetrical peaks and its value increases as tailing becomes more pronounced. 
In some cases, values less than unity may be observed. As peak asymmetry 
increases, integration, and hence precision becomes less reliable. 
 
 
Where, 
            W0.05 = width of peak at 5% height 
f = Distance from the peak maximum to the leading edge of the peak, the 
distance being measured at a point 5% of the peak height from the baseline. 
Limit:  ≤ 2 is preferable.  
1.6.1.7. Height Equivalent to a Theoretical Plate (HETP) 
A theoretical plate can be of any height, which decides the efficiency of 
separation. If HETP is less the column is more efficient. If HETP is more, the column 
is less efficient. The height equivalent to a theoretical plate (HETP) is given by 
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1.7 Basic Statistical Parameters   (Takeru Higuchi, 2001 and Gupta, 1994) 
In analytical chemistry, statistical methods are unavoidable whether it is a 
calibration curve or the result of single or multi analysis interpretation can only be 
ascertained if the margin of error is known, when the measurement is repeated, a 
statistical analysis is compulsory. The total quality control on a statistical basis gives 
promise of making pharmaceutical manufacturing more efficient. 
1.7.1 Linear Regression 
Once a linear relationship has been shown to have a high probability by the 
value of the correlation coefficient ‘r’, then the best straight line through the data 
points has to be estimated. This can often be done by visual inspection of the 
calibration graph, but in many cases it is far more sensible to evaluate the best straight 
line by linear regression (the method of least squares). The equation of straight line is 
y = mx + c 
Where, y the dependent variable is plotted as result of changing x, the 
independent variable. To obtain the regression line ‘y on x’ the slope ‘m’ of the line 
and the intercept ‘c’ on the y axis are given by the following equation. 
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1.7.2. Correlation Coefficient 
To establish whether there is a linear relationship between two variables x1 
and y1, use Pearson’s correlation coefficient r. 
 
Where, n is the number of data points. 
The value of r must lie between +1 and -1, the nearer it is to +1, the greater the 
probability that a definite linear relationship exists between the variables x and y, 
values close to +1 indicate positive correlation and values close to -1 indicate negative 
correlation values of ‘r’ that tend towards zero indicate that x and y are not linearly 
related (they made be related in a non-linear fashion). 
1.7.3. Standard Deviation 
It is commonly used in statistics as a measure of precision and is more 
meaningful than the average deviation. It may be thought of as a root-mean-square 
deviation of values from their average and is expressed mathematically as  
 
Where, SD is Standard deviation 
n = Large (50 or more) then of course it is immaterial whether the term in the 
denomination is n -1 or n 
Σ= Summation 
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x = Mean or arithmetic average 
x -  = Deviation of a value from the mean 
n = Number of observations 
1.7.4. Percentage Relative Standard Deviation (%RSD) 
            It is also known as coefficient of variation. It is defined as the standard 
deviation (S.D) expressed as the percentage of mean.  
 
Where, S D = Standard deviation 
 = Mean or arithmetic average 
The variance is defined as S2 and is more important in statistics than S itself. 
However, the latter is much more commonly used with chemical data. 
1.7.5. Standard Error of Mean (S.E.) 
Standard error of mean can be defined as the value obtained by division of 
standard deviation by square root of number of observations. It is mathematically 
expressed as, 
n
S.D.S.E. =  
Where, S.D = Standard deviation 
n = number of observations 
  
 
LITERATURE 
REVIEW 
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2. LITERATURE REVIEW 
2.1. DRUG PROFILE                                 (www. en.wikipedia.org/wiki/silodosin) 
Silodosin  
Structure (The Merck Index 2006) 
O
NH2
N
OH
NH
O
CH3 O
F
F
F
 
Chemical name        : 2, 3-Dihydro-1(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2, 2, 2                               
trifluoroethoxy) phenoxy] ethyl}amino) propyl] -1H-indole-7-
carboxamide 
Molecular Formula :      C25H32F3N3O4 
Molecular weight :       495.53 
Melting point  :       105-110 
S.No Drug Name Melting Point Average Value 
1. Silodosin 
1080C 
1080C 
1070C 
1070C 
1080C 
107.660C 
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Storage  : Stored in a tightly closed container at room temperature and 
   away from excess heat and moisture. 
Silodosin - α1Adrenergic antagonist 
(http://www.emedicinehealth.com/drug-silodosin/article_em.html)  
Silodosin is in a group of drugs called alpha-adrenergic blockers. Silodosin 
helps relax the muscles in the prostate and bladder neck making it easier to urinate. 
Silodosin is used to improve urination in men with benign prostatic hyperplasia 
(enlarged prostate). 
Side effects 
Silodosin side effects includes signs of an allergic reactions like difficulty 
breathing, swelling of face, tongue, lips or throat and also shows severe dizziness, 
jaundice, penis erection that is painful or lasts 4 hrs or longer, headaches, insomnia, 
diarrhea and sore throat. 
Contraindications 
Silodosin should not be used in patients having severe renal impairment 
(creatinine clearance (ccr (30 mL/min) or liver disease. Silodosin is contraindicated in 
patients taking ketoconozole (Nizoral), Itraconazole (sporanox) or Ritonavir (Norvir). 
Drug interactions 
Some medicines may interact with silodosin. 
Ex. 1) Alpha-blockers (eg. prazosin) or Phosphodiesterace inhibitors (eg. sildenafil) 
because symptoms of low blood pressure (eg. severe dizziness, fainting) may occur. 
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        2) Azole Antifungals (eg. Itraconazole, ketoconazole), Clarithromycin, 
Cyclosporin, Diltiazem, Erythromycin, Flucanozole, Nefazodone, Probenecid, 
Ritonavir, Valproic acid or Verapamil because they may increase the risk of silodosin 
side effects. 
Clinical pharmacology 
Mechanism of action 
Silodosin is a selective antagonist of post synaptic alpha-1 adrenoreceptors, 
which are located in the human prostate, bladder base, bladder neck, prostatic capsule 
and prostatic urethra. Blockade of these alpha-1 adrenoreceptors can cause smooth 
muscles in these tissues to relax, resulting in an improvement in urine flow and a 
reduction in BPH (benign prostatic hyperplasia) symptoms. 
Dosage and Administration 
1) 8 mg capsules taken orally once daily with a meal. 
2) 4 mg capsules taken orally once daily with a meal for those moderate renal 
impairment. (Creatinine clearance (ccr) 30-60 mL/min). 
Pharmacokinetics 
Metabolism 
Silodosin undergoes extensive metabolism through glucuronidation, alcohol 
and aldehyde dehydrogenase, and cytochrome P450 3A4 (CYP3A4) pathways. The 
main metabolite of silodosin is a glucuronide conjugate (KMD-3213G) that is formed 
via direct conjugation of silodosin by UDP-glucuronosyltransferase 2B7 (UGT2B7). 
Co-administration with inhibitors of UGT2B7 (e.g., probenecid, valproic acid, 
fluconazole) may potentially increase exposure to Silodosin. 
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Excretion 
Following oral administration of 14C-labeled silodosin, the recovery of 
radioactivity after 10 days was approximately 33.5% in urine and 54.9% in feces. 
After intravenous administration, the plasma clearance of silodosin was approximately 
10 L/hour. 
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2.2. REPORTED METHODS 
1) Satoshi Tatemichi et al. (2006) 
“Uroselectivity in male dogs of Silodosin (KMD-3213), a novel drug for the 
obstructive component of benign prostatic hyperplasia.” 
Examination of uroselectivities in two sets of experiments namely, in vitro and 
in vivo functional studies using male dogs was done. In the in vitro study, after 
evaluating the inhibitory effects of Silodosin on noradrenaline (NA)-induced 
contractions in the isolated prostate and isolated carotid artery using the Magnus 
method, we calculated prostatic selectivity. In the in vivo study, examination on the 
effects of drugs on the hypogastric nerve stimulation (HNS)-induced increase in 
intraurethral pressure (IUP) and on blood pressure. The uroselectivity of Silodosin 
was compared with those of tamsulosin and naftopidil. Results clearly demonstrate 
that Silodosin is a potent and highly selective α1A-AR antagonist. A selective α1A-AR 
antagonist such as Silodosin may have good potential as a less-hypotensive drug for 
the treatment of urinary dysfunction in benign prostatic hyperplasia patients. 
2) Leonard S Marks et al. (2008) 
“Rapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in 
Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results 
of 2 Phase 3 Studies.” 
Men 50 years or older with an International Prostate Symptom Score of 13 or 
greater and peak urinary flow rate of 4 to 15 mL per second received placebo or 8 mg 
Silodosin daily with breakfast for 12 weeks. The primary end point was International 
Prostate Symptom Score change from baseline to last observation. Change in peak 
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urinary flow rate was a secondary end point.  After 0.5 week (range 3 to 4 days) of 
treatment patients receiving Silodosin vs placebo achieved significant improvement in 
total International Prostate Symptom Score (difference −1.9, p <0.0001) and irritative 
(–0.5, p = 0.0002) and obstructive (–1.4, p <0.0001) subscores.  
3) Tetsuya Takao et al. (2008) 
“Determination of Silodosin in human plasma by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS).” 
Elution - Isocratic 
Solvent - Methyl t-butyl ether 
Column - C(8) column 
Mobile Phase - acetonitrile-10 mM ammonium acetate (40:60, v/v)  
Detector - TurboIonSpray (TIS) ionization and multiple reaction 
monitoring (MRM) in the positive-ion mode 
4) Tomonori Yamanishi et al. (2009) 
 “Urodynamic effects of Silodosin, a new α1A-adrenoceptor selective antagonist, 
for the treatment of benign prostatic hyperplasia.” 
Thirty six male patients with BPH (69.9 ± 7.3 years),who were referred as 
candidates for surgery, were treated with Silodosin (4 mg twice daily). The total 
International Prostate Symptom Score (IPSS) was 20.7 ± 7.4, maximum flow rate 
(Qmax) was 6.7 ± 3.0 mL/sec, and prostate volume was 45.6 ± 24.5 mL. Total IPSS, 
strage and voiding symptom subscores and QOL score decreased significantly, and 
Qmax increased significantly after 1–12 months of therapy (all P < 0.05). In 
urodynamic study Detrusor opening pressure, detrusor pressure at Qmax, bladder outlet 
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obstruction index, and Schäfer's obstruction class decreased significantly after therapy 
(all P < 0.01). 
5) Marc C Gittelman et al. (2010) 
“Effect of Silodosin on specific urinary symptoms associated with benign 
prostatic hyperplasia: analysis of international prostate symptom scores in 2 
phase III clinical studies.” 
Silodosin, auroselective α-blocker, significantly improved International 
Prostate Symptom Scores (IPSS) in men with symptomatic benign prostatic 
hyperplasia (BPH). The clinical trial study was done on Study participants (N = 923) 
were men aged ≥50 years with IPSS ≥13 and Qmax 4–15 mL/s. Decrease in IPSS  and  
Qmax score was observed in patients taking Silodosin (Silodosin, -1.1 ± 1.4 versus 
placebo, -0.5 ± 1.2; P < 0.0001). 
6) Furuya R et al. (2010) 
“Investigation of adverse events and the continuance rate of Silodosin in all 
patients who received Silodosin for lower urinary tract symptoms suggestive of 
benign prostatic hyperplasia.” 
Silodosin is a α1-Aadrenoreceptor antagonist which is used in the treatment of 
Benign prostatic hyperplasia. Investigation was done on 256 volunteers out of which 
61 was rejected due to prostate cancer.196 patients was evaluated for the  International 
Prostate Symptom Score (IPSS), quality of life (QOL) index, uroflowmetry and 
postvoid residual urine volume before and after medication. Adverse events were 
observed in 56 of the 195 cases (28.7%). The most common adverse event was 
abnormal ejaculation (10.8%). The patients who reported adverse events were 
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significantly younger in age and had lower IPSS and QOL index values after 
treatment than those without adverse events. 
7)  Roehrborn C G et al. (2010)  
“Symptomatic and urodynamic responses in patients with reduced or no seminal 
emission during Silodosin treatment for LUTS and BPH.” 
Data from phase 3 studies (NCT00224107, NCT00224120) of Silodosin for 
treatment of BPH symptoms were analyzed to examine the relationship between 
treatment efficacy and occurrence of abnormal ejaculation. Men aged ≥ 50 years with 
International Prostate Symptom Scores (IPSS) ≥ 13 and peak urinary flow rates 
(Qmax) of 4–15 mL s−1 received placebo or Silodosin 8 mg once daily for 12 weeks. 
Silodosin-treated patients were stratified by absence or presence of ‘retrograde 
ejaculation’ (RE).  Of the 466 patients receiving Silodosin, 131 (28%) reported RE 
and 335 (72%) did not; 4 of the 457 patients receiving placebo (0.9%) reported RE. 
Silodosin-treated patients with (+) and without (−) RE showed significant 
improvement in IPSS, Qmax and quality of life versus placebo (P<0.02).  
8) Miho Watanabe et al. (2010) 
 “Effects of Silodosin on Lower Urinary Tract Symptoms in Patients with Benign 
Prostatic Hyperplasia: Evaluation by Frequency/Volume Chart.” 
The study was done on Forty male patients (71.1 ± 6.6 years old) with 
LUTS/BPH were treated with Silodosin (4 mg twice daily). The effects of the drug 
were assessed by changes in International Prostate Symptom Score, uroflowmetry, 
and frequency/volume chart at 1 and 3 months after therapy. The frequency/volume 
chart showed that daytime frequency in those who initially voided over eight 
times/day (n = 12) decreased significantly (P = 0.0391) after 1 month, and nighttime 
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frequency in those who initially voided over two times (n = 16) tended to decrease 
(P = 0.0833) after 3 months. 
9) Hideshi Miyakita et al. (2010) 
“Short-term effects of crossover treatment with Silodosin and tamsulosin 
hydrochloride for lower urinary tract symptoms associated with benign prostatic 
hyperplasia.” 
A randomized cross over method was done by  comparing the efficacy and 
safety of Silodosin and tamsulosin in patients with lower urinary tract symptoms 
(LUTS) associated with benign prostatic hyperplasia (BPH). Intergroup comparison of 
changes revealed that Silodosin showed significant improvement of straining and 
nocturia with first and crossover treatments, respectively, compared with tamsulosin. 
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3. AIM AND PLAN OF WORK 
3.1 Aim of Work 
The prime importance of drug analysis is to gain information about the 
qualitative and quantitative composition of substance and chemical species, that is to 
find out what a substance is composed of and exactly how much.  
This information guides development of the manufacturing operations and 
therapeutic action of drugs.  
 Standard analytical procedure for newer drugs or its formulation may not be 
available in Pharmacopoeias. Hence it is essential to develop newer analytical 
methods which are accurate, precise, specific, linear, simple and rapid. 
Silodosin is a newer drug which was recently approved in 2011 and not  yet 
developed any RP-HPLC and UV spectroscopic methods.  
Hence the present study aims to develop simple, precise and accurate methods 
for the determination of Silodosin by simple UV methods and RP-HPLC method in 
capsule formulation. 
3.2 Plan of Work 
 The extensive survey of literature for Silodosin regarding their physiochemical 
properties, pharmacological properties and analytical methods. This formed 
the basis for the development of methods. 
 Selection and collection of Silodosin working standard for analysis. 
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 Identification of working standard by IR spectroscopy, Melting point and 
chemical tests. 
 Selection of suitable solvent for quantitative extraction of drug present in the 
capsules. The solvent should be readily available, economical and of analytical 
grade for UV-spectroscopy and HPLC grade for RP-HPLC and should not 
chemically interact with the compound of interest and its structural 
characteristics. 
 Selection of suitable method for analysis depending upon the spectral 
characteristics of the drug. 
 Selection of suitable wavelength for rapid, accurate, precise and simple UV 
spectroscopic methods development. 
 Development of rapid and accurate RP-HPLC method by using UV detector. 
 Analysis of marketed available individual formulations by the UV 
Spectroscopic methods and RP-HPLC Methods. 
 Statistical analysis of developed analytical methods. 
 Validation of analytical methods as per the ICH guidelines. 
 
 
  
 
MATERIALS 
AND METHODS 
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4. MATERIALS AND METHODS 
4.1. MATERIALS USED 
4.1.1. Drugs  
Silodosin was supplied as a gift sample by MSN Laboratories Ltd., Hyderabad. 
4.1.2. Reagents & Chemicals 
Methanol was purchased from Thermo Fisher scientific India Pvt. Ltd. Fresh 
serum used in the method development was obtained from the S.V Real Diagnostics-
74, Vachalapuram, Thiruninravur, Chennai-602024. Capsules (Silodol-4 and Silodal-
8) were purchased from local market, containing Silodosin 8mg, per capsule. 
4.1.3. Instruments Specifications 
1) Shimadzu AX – 200 digital balances: (Shimadzu instruction manual) 
Specifications 
Weighing capacity 200 gms 
Minimum display 0.1 mg 
Standard deviation ≤ 0.1 mg 
Operation temperature range  5 to 40° C 
 
2) Shimadzu UV – Visible spectrophotometer: (Shimadzu instruction manual) 
Model : Shimadzu, UV-1700, Pharmaspec. Cuvetts: 1 cm matched quartz cells 
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Instrumentation 
 A UV-visible spectrophotometer (1700 shimadzu) with spectral bandwidth 1 
nm was employed for all spectroscopic measurements, using a pair of 10 mm matched 
quartz cells. 
Specifications 
Light source 
20 W halogen lamp, Deuterium lamp.Light source 
position automatic adjustment. 
Monochromator Aberration-correcting concave holographic grating 
Detector Silicon Photodiode 
Stray Light 
0.04% or less (220 nm: NaI 10 g L-1) 
0.04% or less (340 nm: NaNo2 50 g L-1) 
Measurement 
wavelength range 
190~1100 nm 
Spectral Band Width 1 nm or less (190 to 900 nm) 
Wavelength Accuracy ± 0.5 nm automatic wavelength calibration 
mechanism 
Recording range 
Absorbance : -3.99~3.99 Abs 
Transmittance : -399~399% 
Photometric Accuracy ± 0.004 Abs (at 1.0 Abs), ±0.002 Abs (at 0.5 Abs) 
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3) Thermo scientific Spectra High Performance Liquid Chromatography:  
Instrument Specifications 
Pump P4000 
Auto sampler AS3000 
UV-Vis Detector UV 2000 
Vacuum Degasser SCM 1000 
System Controller SN4000 
Software Chrom Quest 
 
4) Sonica ultra sonic cleaner- model 2200 MH 
5) ELICO – pH meter model L1610 
6) Micropipette 
7) Melting point apparatus - Guna enterprises Chennai  
4.2. Methods Employed 
The methods employed for the estimation of silodosin are  
4.2.1. UV Spectrophotometric method 
Method-I 
a) Simple UV spectroscopic method 
Method-II 
b) First order  derivative spectroscopic method   
Method-III 
c) Geometric Correction method 
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Method-IV 
Colorimetric method 
Identification of Drugs 
 Silodosin working standards were identified from their Infra Red spectrum, 
Melting point, Spectral identification tests and chemical tests.  
Selection of solvent 
 The solubility of Silodosin was determined in a variety of solvents as per 
Indian pharmacopoeia standards. Solubility was carried out in polar to nonpolar 
solvents. From the solubility data methanol was selected as solvent for the analysis of 
Silodosin. 
Method I and II 
Preparation of standard stock solution and Selection of wavelengths 
Accurately weighed 25 mg of Silodosin raw material and was transferred in to 
25 mL volumetric flask and dissolved in methanol and made up to the volume with 
methanol. This solution contains 1mg mL-1 concentration. The standard stock solution 
was further diluted with methanol to get the concentration of 10 µg mL-1 and the 
solution was scanned between 200 to 400 nm using methanol as blank. From the 
spectra, Silodosin showed maximum absorbance at 269.5nm. In method II, the zero 
order spectra was derivitized in to first order derivative spectra and 230 nm 
wavelength was selected. Stability studies were carried out at their λmax and Silodosin 
was found to be stable for 4 hrs. 
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Linearity and calibration graph 
The standard stock solution containing 1000 µg mL-1 was further diluted to get 
the concentration of 100 µg mL-1 of Silodosin. The working stock solution of 
Silodosin (0.5-2.5 mL) was transferred into series of five 10 mL volumetric flasks and 
made up to the volume with methanol. The absorbance of different concentration 
solutions were measured at their selected wavelengths. The calibration curve was 
constructed by plotting concentration against absorbance for zero order and derivative 
methods. Silodosin was linear with the concentration range of 5 – 25 µg mL-1   at their 
selected wavelengths. 
Quantification 
Twenty capsules of Silodosin (silodal-4) were weighed respectively. An 
accurately weighed quantity of the fine powder equivalent to 25 mg of Silodosin was 
transferred to a 10 mL volumetric flask. The contents were ultrasonicated for 15 min 
with methanol, made to volume with methanol and filtered through whatmann filter 
paper no.41.The solution was further diluted with methanol, to give concentration of 
10 µg mL-1 of Silodosin. Absorbance of these solutions was measured at their selected 
wavelengths using methanol as blank. The amount of Silodosin present in formulation 
was calculated from the slope and intercept of respective calibration curve. 
Recovery studies 
% recovery experiments were performed at three different levels i.e. 80%, 
100% and 120%.To the 50% of the pre analyzed sample solution, a known amount of 
standard solution was added and the contents were mixed well and finally made up to 
the volume with methanol. Absorbance was measured at their selected wavelengths. 
Amount present was calculated from slope and intercept. The % recovery was 
determined by using the following formula. 
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Where,    N =Number of observations 
                X=Amount added in µg/mL. 
                Y=Amount recovered in µg/mL. 
 Method-III [Geometric Correction method] 
In method III, three wavelengths were (257, 269, and 284) selected for 
Geometric correction method. Stability studies were carried out at their selected 
wavelengths and Silodosin was found to be stable for 4 hrs. 
Preparation of standard stock solution [without serum] 
Accurately weighed 25 mg of Silodosin raw material and was transferred in to 
25 mL volumetric flask and dissolved in methanol and made up to the volume with 
methanol. This solution contains 1mg mL-1 concentration. 
Linearity and calibration graph [without serum] 
The standard stock solution containing 1000 µg mL-1 was further diluted to get 
the concentration of 100 µg mL-1 of Silodosin. From the working stock solution of 
Silodosin (0.5-2.5 mL) was transferred into series of five 10 mL volumetric flasks and 
made up to the volume with methanol. The absorbance of different concentration 
solutions were measured at their selected wavelengths.  
Preparation of standard stock solution [with serum] 
Accurately weighed quantity of 25 mg of Silodosin raw material was added in 
to the 25 mL of serum and sonicate for 15 min. This solution contains 1mg mL-1 
concentration. 
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Linearity and calibration graph [with serum] 
The standard stock solution containing 1000 µg mL-1 was extracted with 
methanol to get the concentration of 100 µg mL-1 of Silodosin. From the working 
stock solution of Silodosin (0.5-2.5 mL) was transferred into series of five 10 mL 
volumetric flasks and made up to the volume with methanol. The absorbance of 
different concentration solutions were measured at their selected wavelengths. For the 
Geometric correction method, Corrected absorbance were found by using the 
following equation 
 Corrected absorbance, D =  
y= (λ2-λ1) 
z= (λ3-λ2) 
A1= Absorbance of the sample solution at λ1 
A2= Absorbance of the sample solution at λ2 
A3= Absorbance of the sample solution at λ3 
v = vD/D [absorbance ratio of drug in methanol (without serum) at λ1 and λ2] 
w = wD/D [absorbance ratio of drug in methanol (without serum) at λ3 and λ2] 
The calibration curve was constructed by plotting concentration against 
corrected absorbance. 
Quantification with serum 
Twenty capsules of Silodosin (Silodal) were accurately weighed and the 
capsule powder equivalent to 25 mg of Silodosin was added in to the 25 mL of serum 
taken in a 25 mL volumetric flask. The contents were ultrasonicated for 15 min. From 
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the above solution containing 1 mg mL-1, 2.5 mL of solution was transferred in to 25 
mL standard flask, 10 mL of methanol was added and made up to the volume with 
methanol and filtered through whatmann filter paper no.41. 
The solution was further diluted with methanol, to give concentration of 10 µg 
mL-1 of Silodosin. Absorbance of these solutions was measured six times at their 
selected wavelengths (284nm, 269nm, 257nm) using methanol as blank. 
Quantification without serum 
The above same procedure was repeated without serum sample. The amount of 
Silodosin present in formulation was calculated by using corrected absorbance from 
the slope and intercept of respective calibration curve. 
Recovery studies [with Serum]  
The recovery experiment was done by adding known concentrations of 
Silodosin working standard to the 50% pre analyzed formulations. Standard silodosin 
raw material solutions were prepared in methanol. Suitable amount of standard 
solutions containing concentrations of Silodosin equivalent to 80 %, 100 % and 120% 
of the test concentration were added to the 50% pre analyzed formulation.  
Recovery studies [without Serum]  
The recovery experiment was done by adding known concentrations of 
Silodosin working standard to the 50% pre analyzed formulations. Standard Silodosin 
raw material solutions were prepared in methanol. Suitable amount of standard 
solutions containing concentrations of Silodosin equivalent to 80 %, 100 % and 120% 
of the test concentration were added to the 50% pre analyzed formulation. The 
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corrected absorbances for geometric correction method of the resulting solutions were 
measured at the selected wavelengths for the determination of Silodosin. The amount 
of each drug recovered was calculated. The procedure was repeated for three times. 
Method IV [Colorimetric method] 
Visible Spectrophotometric Method 
Principle 
 MBTH reagent is a 3-methyl 2-benzthiazolinone hydrazone hydrochloride. It 
is known that secondary amine undergoes oxidation to give hydroxylamine with ceric 
ammonium sulphate (CAS) which converts into stable nitroxides and gives orange red 
colour complex with MBTH reagent. The colour intensity obtained by adding this 
reagent was measured at 508 nm.  
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Preparation of the reagent 
 0.4% MBTH reagent was prepared by weighing 400 mg of MBTH  reagent into 
100 mL volumetric flask and added minimum quantity of 0.1M HCl to dissolve the 
substance and made up to mark with 0.1M HCl.  
Preparation of 0.008% ceric ammonium sulphate 
 0.5056 gm of ceric ammonium sulphate was weighed and transferred in to a 
100 mL standard flask and dissolved  by adding a little amount of 1M H2SO4 and 
made up to the mark with 1M H2SO4. 
Preparation of 1M H2SO4 
5.7 mL of concentrated sulphuric acid was taken in a 100 mL standard flask 
and made up to the mark with distilled water. 
Selection of solvent 
  From the solubility profile 0.1M HCl was selected as solvent for the analysis 
of Silodosin by colorimetric method. 
Preparation of standard stock solution 
 25 mg of silodosin raw material was weighed accurately and transferred in to 
25 mL volumetric flask, dissolved in 0.1M HCl and made up to the volume with more 
0.1M HCl. The solution contains 1000 µg/ mL concentration. 
Selection of wavelength for estimation and stability studies 
 5 mL of standard stock solution of Silodosin was pipette out in to 50 mL 
standard flask which contains 100 µg/ mL. From the above solution 1 mL of solution 
was transferred in to 10 mL standard flask. To this 1 mL of (0.4%) MBTH reagent and 
4 mL of ceric ammonium sulphate were added and kept for 15 minutes. The volume 
was made up to the mark with distilled water to get concentration of 10 µg/ mL. The 
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orange red coloured chromogen was scanned in visible region (400 – 800 nm) against 
reagent blank. From the spectra the wavelength 508 nm (λ max) was selected. 
 The stability was performed by measuring the absorbance of same solution at 
different time intervals. It was observed that Silodosin was stable for up to three hour 
at the selected wavelength. 
Optimization of reagents 
 The absorbance of Silodosin in different volumes of ceric ammonium sulphate, 
different strengths and volumes of MBTH reagent were optimized to get steady 
absorbance. 
 10 mg of Silodosin raw material was weighed and transferred in to 10 mL 
volumetric flask and dissolved in 0.1M HCl and made up to the volume with more 
0.1M HCl. The solution contains 1 mg/ mL. The solution was further diluted to get the 
concentration of 100 µg/ mL. 
 The volume of ceric ammonium sulphate was optimized by taking 1 mL of 
standard drug solution  in six separate 10 mL volumetric flasks in which constant 
volume of 1 mL of MBTH reagent and 1 – 7 mL of ceric ammonium sulphatewere 
added and made up to the volume with 0.1M HCl. The absorbance of the solution in 
each standard flask was measured at 508 nm against reagent blank.  
 The volume of reagent was optimized by taking 1 mL of standard drug 
solution in seven separate 10 mL volumetric flasks in which 1 - 5 mL of (0.4%) 
MBTH reagent and constant volume of 4 mL ceric ammonium sulphate were added 
and made up to the volume with 0.1M HCl. The absorbance of the solution in each 
standard flask was measured at 508 nm against reagent blank. 
 The strength of reagent was optimized by  taking 1 mL of standard drug 
solution  in five separate 10 mL volumetric flasks in which 1 mL of MBTH reagent of 
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each strength (0.1% - 0.5%) and constant volume of 4 mL ceric ammonium sulphate 
was added and made up to the volume with distilled water. The absorbance of the 
solution in each standard flask was measured at 508 nm against reagent blank. 
 It was found that 4 mL of ceric ammonium sulphate and 1 mL of 0.4% MBTH 
reagent were showed marked absorbance.  
Preparation of calibration graph 
 The standard stock solutions of Silodosin (1 – 5 mL) were transferred into a 
series of 10 mL volumetric flasks. To each flask 1 mL of 0.4% of MBTH reagent, 4 
mL of ceric ammonium sulphate were added and made up to the volume with 0.1M 
HCl. The absorbance of different concentration solutions were measured at 508 nm. 
The calibration curve was plotted. Silodosin was linear with the concentration range 
of 10 – 50 µg mL-1 at 508 nm.  
Quantification of formulation  
 Ten capsules (Silodal containing Silodosin equivalent to 8 mg) were weighed 
accurately and the average weight of each capsule was found. The capsule powder 
equivalent to 25 mg of Silodosin was weighed and transferred into 25 mL volumetric 
flask, added a minimum quantity of 0.1M HCl to dissolve the substance and made up 
to the volume with the same (1000 µg mL-1). The solution was sonicated for 15 
minutes, centrifuged for another 15 minutes at 2000 rpm and filtered through 
Whatmann filter paper  No. 41. From the clear solution pipette out 7.5 mL into a 10 
mL volumetric flasks and made up to the volume with 0.1M HCl. From the above 
solution, 1 mL of test solution was transferred in to a series of six 25 mL flasks and  
added 1 mL of 0.4% MBTH reagent, 4  mL of ceric ammonium sulphate, and volume 
was made up to the mark with 0.1M HCl. The absorbances of solutions were 
measured at 508 nm. This procedure was repeated for six times.    
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Recovery 
% recovery experiments were performed at three different levels i.e. 80%, 
100% and 120%. To the pre analyzed sample solution, a known amount of standard 
solution was added and the contents were mixed well and finally made up to the 
volume with 0.1M HCl. Absorbance of these solutions were measured at 508 nm. This 
procedure was repeated for three times. The % recovery was determined by using the 
following formula. 
 
Where,    N =Number of observations 
                X=Amount added in µg mL-1. 
                Y=Amount recovered in µg mL-1. 
LOD and LOQ 
 The linearity study was carried out for six times. The LOD and LOQ were 
calculated based upon the calibration curve method. The LOD and LOQ were 
calculated by using the average of slope and standard deviation of intercept. 
Validation of developed methods 
Linearity and Range 
 From the calibration graphs plotted, silodosin shows the linearity in the range 
of 5-25 µg mL-1, for the UV- Spectroscopic method, Derivative spectroscopic method 
and Geometric correction method, 10-50 µg mL-1 for Colorimetric method 
respectively. 
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Accuracy (Recovery studies)  
 Accuracy of the method was confirmed by recovery studies. The % RSD was 
calculated and tabulated. 
Precision 
            The repeatability of the method was confirmed by the analysis of capsules 
repeated for 6 times with the same concentration. The amount of each drug present in 
the capsules was calculated. The percentage RSD was calculated. The intermediate 
precision of the method was confirmed by intraday and interday analysis i.e. the 
analysis of capsules was repeated three times in the same day and on three successive 
days. The amount of drugs was determined and the percentage RSD was calculated.     
Ruggedness  
 Ruggedness of the method was confirmed by the analysis of the capsules done 
by the different analysts. The amount and % RSD were calculated. 
LOD and LOQ 
 The linearity study was carried out for six times. The LOD and LOQ were 
calculated by using the average of slope and standard deviation of intercept. 
4.2.2. REVERSE PHASE – HPLC METHOD 
Selection of chromatographic method 
        Proper selection of the method depends upon the nature of sample, polarity, 
molecular weight, pKa value and solubility. The drug Silodosin for the present study 
was polar. Therefore reverse phase chromatographic technique was selected by using 
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C18 column as a stationary phase with different ratios of Acetonitrile, Buffer: 1 mL 
triethylamine in 1000 mL water (pH - 3) as a mobile phase. 
Preparation of mobile phase 
 The mobile phase was prepared by mixing Acetonitrile with Buffer: 1 mL 
triethylamine in 1000 mL water   pH 3 (pH adjusted with orthophosphoric acid), in the 
ratio of 22:78% v/v and sonicated for 15 minutes to degas the mobile phase.  
Method Development and Optimization of Chromatographic Conditions 
Preparation of standard stock solution for RP-HPLC 
 80 mg of Silodosin raw material was accurately weighed and transferred into 
100 mL volumetric flask and dissolved in methanol (HPLC grade), after dissolution 
the volume was made up to the mark with methanol (HPLC grade). The solution was 
observed to contain 800 µg/ mL.   
Selection of Detection wavelength
 
 Solution of Silodosin (10 µg/ mL) was made by diluting the stock solution in 
the mobile phase of Acetonitrile: Buffer (1 mL triethylamine in 1000 mL water   pH 3 
(22: 78% v/v) and scanned in the UV region of 200 – 400 nm and recorded the 
spectrum. From spectra at 270, the drug showed maximum absorbance. Hence this 
was selected as a detection wavelength for better sensitivity.  
Stability of sample solutions 
 The standard stock solution (800 µg mL-1) was further diluted with mobile 
phase to get concentration of 10 µg mL-1 and the absorbance was checked for its 
stability at 270 nm. The stability was performed by measuring the absorbance of same 
solution at different time intervals. It was found that Silodosin was stable up to three 
hours. 
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Optimization of Chromatographic Conditions 
Initial separation conditions 
 The following chromatographic conditions were preset initially to get better 
resolution of Silodosin. 
Mode of operation - Isocratic 
Stationary phase - C18 column (150 mm × 4.6 mm i.d. 5µ) 
Mobile phase - Acetonitrile: Buffer (1 mL triethylamine in 1000                                  
mL water pH 3 (pH adjusted with orthophosphoric 
acid) 
Proportion of mobile phase - 50: 50% v/v 
Detection wavelength - 270 nm 
Flow rate - 1 mL min-1 
Temperature - Ambient 
Operating pressure - 80 kgf 
Method -       External Standard Calibration method 
 The mobile phase was primarily allowed to run for 60 minutes to record a 
steady baseline. The solution of Silodosin was injected and the respective 
chromatogram was recorded. It was found that Silodosin was eluted at 1.36 minutes 
and the peak splitting was observed. For this reason different ratios of mobile phase 
with different solvents were tried to obtain good chromatogram with acceptable 
system suitability parameters. 
Selection of mobile phase 
           Different mixtures of mobile phase with different ratios were selected and their 
chromatograms were recorded, they include the following 
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S.No Mobile phase Observation 
1 
 Acetonitrile : Water 
     ( 50: 50% v/v) 
Silodosin was eluted with less retention 
time. 
Peak was broad. 
2 
Acetonitrile : Water 
    ( 80: 20% v/v) 
Silodosin was not eluted proper because of 
more tailing. 
3 
Acetonitrile: Methanol  
( 50: 50% v/v)  
Silodosin was eluted with less retention 
time. 
4 
Acetonitrile : Buffer 
pH3.adjusted with 
orthophosphoric acid 
( 50: 50% v/v) 
A broad peak was observed. 
5 
Acetonitrile: Buffer 3 adjusted  
with orthophosphoric acid  
(22: 78% v/v) 
A Sharp peak was eluted with sufficient 
retention time. 
  
 From the above information, in the mobile phase of Acetonitrile: Buffer pH 
3.adjusted with orthophosphoric acid (22: 78% v/v), the drug was eluted with sharp 
peak. Hence this mobile phase was used to optimize the chromatographic conditions.   
 
Effect of ratio of mobile phase 
The different ratios of Acetonitrile: Buffer pH adjusted to 3 with 
orthophosphoric acid was tried. The ratios tried were 50: 50% v/v, 30: 70% v/v, 
22: 78% v/v and 20 : 80% v/v. From this 22: 78% v/v ratio was selected for further 
analysis. 
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Effect of pH 
The different pH of water tried was 3, 3.5, 4, 4.5. At pH 3 the peak was very sharp. 
Hence this pH was selected for analysis of Silodosin.  
Optimized Chromatographic Conditions 
Mode of operation - Isocratic 
Stationary phase - C18 column (150 mm × 4.6 mm i.d. 5µ) 
Mobile phase - Acetonitrile: Buffer (1 mL triethylamine in 1000                        
mL water pH 3 (pH adjusted with orthophosphoric 
acid) 
Proportion of mobile phase - 22: 78 % v/v 
Detection wavelength - 270 nm 
Flow rate - 1 mL/ min 
Temperature - Ambient 
Sample load - 20 µL 
Operating pressure - 80 kgf 
Method -       External Standard Calibration method          
Preparation of standard stock solution 
 80 mg of Silodosin raw material was weighed and transferred into100 mL 
volumetric flask, dissolved in methanol (HPLC grade) and made up to the volume 
with same (stock solution). Further dilution was made to get the concentration of 10 
µg/ mL with mobile phase (working standard solution). 
Preparation of Calibration graph 
 In this method, the aliquots of 7 – 13 mL of working standard of Silodosin 
were transferred into 100 mL volumetric flasks and made up to the mark with mobile 
phase. The solutions are containing the concentration of 56 – 104 µg mL-1 of 
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Silodosin. All the solutions were injected and the chromatograms were recorded at 
270 nm. The above concentration range was found to be linear and obeys Beer’s law. 
The procedure was repeated for three times. The peak areas were plotted against 
concentration and the calibration curve was constructed. 
Estimation of Silodosin in capsule formulation 
 Estimation of Silodosin by RP – HPLC was carried out using optimized 
chromatographic conditions. Silodal capsules containing 8 mg of Silodosin were 
weighed accurately. The average weight was found. The capsule powder equivalent to 
25 mg of Silodosin was weighed and transferred into 25 mL volumetric flask and 
added a minimum quantity of methanol to dissolve the substance and made up to the 
volume with the same (1000 µg mL-1). The solution was sonicated for 15 minutes, 
centrifuged at 2000 rpm for 15 minutes and filtered through 0.45 µ nylon membrane 
filter. Clear solution was obtained.  
MIDDLE LEVEL: 
 From the clear solution obtained above, 0.8 mL was transferred in to a 10 mL 
volumetric flask and made up to the volume with mobile phase (80 µg mL-1). The 
same procedure was repeated for three times. 
LOW LEVEL: 
 From the clear solution obtained above, 0.64 mL was transferred in to a 10 mL 
volumetric flask and made up to the volume with mobile phase (64 µg mL-1). The 
same procedure was repeated for three times. 
HIGH LEVEL: 
 From the clear solution obtained above, 0.96 mL was transferred in to a 10 mL 
volumetric flask and made up to the volume with mobile phase (96 µg mLµg/ mL). 
The same procedure was repeated for three times. After the stabilization of base line 
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for 30 minutes, nine (3*3) test solutions of formulation were injected and recorded the 
chromatograms. The concentration of each test solution was determined by using 
slope and intercept values from the calibration graph. 
Recovery Experiments  
a) Preparation Silodosin raw material stock solution 
 An accurately weighed quantity of 25 mg of Silodosin was transferred into 25 
mL volumetric flask and added sufficient methanol (HPLC grade) to dissolve the 
substance and made up to the mark with the same. This contains 1 mg/ mL 
concentration.  
b) Procedure 
 The recovery experiment was done by adding known concentrations of raw 
material stock solution of Silodosin to the preanalyzed formulation. The capsule 
powder equivalent to 8 mg of Silodosin was weighed accurately and added 0.8 mL, 
1.6 mL, and 2.4 mL of raw material stock solution into 100 mL standard flasks 
individually and dissolved in mobile phase and made up to the mark with same. The 
solution was sonicated for 15 minutes. After sonication, centrifuged for further 15 
minutes at   2000 rpm and the solution was filtered through a 0.45 µ nylon membrane 
filter. The procedure was repeated as per the analysis of formulation. The amount of 
drug recovered was calculated by using slope and intercept values from the calibration 
graph.   
LOD and LOQ 
 The linearity study was carried out for six times. The LOD and LOQ were 
calculated based upon the calibration curve method. The LOD and LOQ were 
calculated using the average of slope and standard deviation of intercept. 
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System suitability studies 
 The system suitability studies conceded as per ICH guidelines and USP. The 
parameters like tailing factor, asymmetry factor, capacity factor, number of theoretical 
plates and HETP were calculated. 
  
RESULTS  
AND 
DISCUSSION 
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5. RESULTS AND DISCUSSION 
Two simple, rapid, precise and accurate UV - Visible spectrophotometric methods, 
Geometric correction method, Colorimetric method and isocratic RP – HPLC methods 
were developed and validated for estimation of Silodosin in pure form and in capsule 
dosage form. 
The methods employed for the analysis of Silodosin are 
I. UV spectroscopic method 
1. Simple UV method 
2. First Order Derivative method 
3. Geometric Correction method 
II. Visible spectrophotometric method  
III. RP – HPLC method 
5.1. UV Spectroscopic method  
Silodosin was obtained as a gift sample from MSN Labaratories Ltd, Hyderabad and 
was identified by IR spectrum as shown in Figure 1 and melting point analysis. 
 The solubility of Silodosin was determined as per Indian pharmacopoeia. From the 
solubility data Silodosin is very soluble in methanol, freely soluble in dimethyl formamide, 
ethanol, dilute acetic acid, soluble in 0.1M Hydrochloric acid, N-butanol and insoluble in 
methanol. Dimethyl formamide, chloroform has longer cut off wavelength. With Dilute 
acetic acid, 0.1M Hydrochloric acid the absorbance was very low and spectrum was not 
proper. From the remaining solvents, Methanol was selected for easy preparation of solvent 
and shorter cut off wavelength, this may not interfere the spectra of Silodosin during the 
analysis. Hence, methanol was selected as a solvent for UV method, because of its 
solubility, stability and easy availability. The solubility data are shown in Table 1. 
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Silodosin was dissolved in methanol and made further dilutions with methanol to 
get the concentration of 10 µg mL-1. The spectrum of Silodosin was recorded and the 
wavelength maximum was found to be 269.5 nm. This was selected as analytical 
wavelength. The spectrum was shown Figure 2. The stability of the drug was studied by 
measuring the absorbance at different time intervals. The drug was stable up to 4 hours in 
methanol.  
Different aliquots of Silodosin were prepared in the concentrations of 5-25 µg mL-1. 
The absorbances of solutions were measured at 269.5 nm. The calibration curve was plotted 
using concentration against absorbance. The preparation of calibration curve was repeated 
for six times. The optical characteristics like Correlation coefficient, Slope, Intercept, Molar 
absorptivity, Sandell’s sensitivity, LOD and LOQ were calculated. The correlation 
coefficient value for the calibration graph was found to be 0.9999. This indicates that the 
drug obeys Beer’s law in the concentration range of 5 – 25 µg mL-1. Hence the 
concentration was found to be linear. The calibration curve of Silodosin at 269.5 nm is 
shown in Figure 3. The optical characteristics are listed in Table 2.                   
Silodal capsules (MSN Laboratories Ltd, Hyderabad containing 4mg of Silodosin) 
were selected for analysis. The nominal concentration of Silodosin from the linearity was 
prepared and the absorbance of the solution was measured at 269.5 nm. The amount of test 
solution was calculated by using slope and intercept values. This procedure was repeated 
for six times to ensure the precision of the method. The percentage label claim in capsule 
formulation was found to be 100.37 ± 1.662. The amount present in capsule formulation 
was good concord with the label claim and the Percentage Relative Standard Deviation (% 
RSD) value was found to be 1.657. The low % RSD value indicates that the method has 
good precision. The results of analysis are shown in Table 3. 
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The intermediate precision of the method was confirmed by Intraday and Inter 
day analysis. The analysis of formulation was repeated for three times in the same day 
and one time in the three successive days. The percentage RSD value for intraday and 
inter day analysis of Silodosin was found to be 0.3768 and 1.9225, respectively. The 
reports of analysis are shown in Tables 4 and 5. The results showed that the precision of 
the method was further confirmed.  
The developed method was validated for Ruggedness. It refers to the specific of 
one lab to multiple labs which may include multiple analysts, multiple instruments and 
different sources of the reagents and so on. In the present work, it was confirmed by 
different analysts and different instrument. The percentage RSD value for analyst 1 and 
analyst 2 was found to be 0.0684 and 1.3827, respectively. The % RSD value for 
instrument 1 was found to be 1.3993 and for instrument 2 was found to be 1.2878. The 
low % RSD values indicate that the method was more rugged. Reports of analysis are 
shown in Tables 6 and 7 for different analyst and different instrument, respectively. 
The accuracy of the method was confirmed by recovery studies. To the 50 % 
preanalyzed formulation a known quantity of Silodosin raw material solution was 
added at three different concentrations. The absorbances of the solutions were 
measured and the percentage recovery was calculated.  The percentage recovery was 
found to be in the range of 99.4% to 100.5% of Silodosin. The % RSD was found to be 
less than 2. The low % RSD values indicated that there are no interferences due to 
excipients used in formulation during the analysis of Silodosin from tablets 
formulation. Hence the method was found to be accurate. The recovery data are shown 
in Table 8. 
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5.2 Derivative Spectrophotometric Method 
The zero order spectrums were derivatised into first order derivative 
spectrums. The first order derivative spectrum of silodosin was recorded as shown in 
Figure 4. From the spectrum, 230 nm was selected for the estimation of silodosin, 
which has maximum absorbance at this wavelength. Aliquots of silodosin were 
prepared in the concentration range of 5-25 µg mL-1. The ∆A/∆λ value of these 
solutions was measured at 230 nm in the first order derivative spectrum for silodosin. 
The plotted calibration curves were shown in Figure 5 for silodosin respectively. The 
preparation of calibration curve was repeated for six times at their selective 
wavelength. The calibration curve was plotted using concentration against ∆A/∆λ. 
The optical parameters like, Sandell’s sensitivity, Molar absorptivity, correlation 
coefficient, slope, intercept, LOD, LOQ and Standard error were calculated for both 
the drugs. The correlation coefficient of the drug was found to be above 0.9998. This 
indicates that the drug obeys Beer’s law and they were linear at the selected 
concentration range. The results are shown in Table 9.  
 For Quantification, the concentration of solution containing 10 µg mL-1 of 
silodosin was prepared and measured at their respective wavelengths.  The amount of 
six test solutions was determined. The percentage purity of capsules was found to be 
98.77 ± 0.7989 for silodosin, respectively. The amount present in capsules was in 
good concord with the label claim and the % RSD values were found to be 0.8088 for 
Silodosin, respectively. The results of analysis are shown in Table-10. The low % 
RSD values indicate that the method has good precision.  
Further, the precision of the method was confirmed by Intra-day and Inter-day 
analysis. The analysis of capsules was carried out for three times in the same day and 
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one time in the three consecutive days. The % RSD value of Intra-day and Inter day 
analysis are 1.1254 and 1.7766 for Silodosin respectively. The results of analysis are 
shown in Table 11and 12. Hence the precision was confirmed.  
            The developed method was validated for Ruggedness. In the present work, 
ruggedness was confirmed by different analysts. The % RSD value by analyst 1 and 
analyst 2 were found to be 0.0684 and 1.3755 for Silodosin, respectively. The low % 
RSD value indicates that the developed method was more rugged. The results are 
shown in Table 13 and 14. 
 The accuracy of the method was performed by recovery studies. To the 50% 
preanalysed formulation, a known quantity of Silodosin raw material solutions was 
added at three different concentration levels. The absorbance of the solutions was 
measured and the percentage recovery was calculated. The percentage recovery was 
found to be in the range of 99.4 – 100.73%. The average %RSD values of Silodosin 
were found to be 0.4353 respectively. The low % RSD values of the drugs reveals that 
the method was more accurate. The recovery data was shown in Table 15. 
5.3. Geometric correction method 
A number of mathematical correction procedures have been developed which 
reduce or eliminate the background irrelevant absorption that may be present in 
samples of biological origin. The simplest of these procedures is the three-point 
geometric procedure, which may be applied if the irrelevant absorption is linear at the 
three wavelengths selected. In this method, three wavelengths 257, 269, and 284 nm 
were selected for the estimation of Silodosin in Serum and in without serum. Based 
on the absorbance the corrected absorbance was calculated by using the following 
equation 
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Corrected absorbance, D =  
y= (λ2-λ1) 
z= (λ3-λ2) 
A1= Absorbance of the sample solution at λ1 
A2= Absorbance of the sample solution at λ2 
A3= Absorbance of the sample solution at λ3 
v = vD/D [absorbance ratio of drug in methanol (without serum) at λ1 and λ2] 
w = wD/D [absorbance ratio of drug in methanol (without serum) at λ3 and λ2] 
The linearity of the drug was checked at 5-25 µg mL-1. The plotted calibration 
curves were shown in figure 6 for Silodosin, respectively. In this method, Silodosin 
was estimated with serum, without serum and the combined spectrum were recorded 
shown in Figure 7, 8 and 9. The preparation of calibration curve was repeated for six 
times for each drug at their selective wavelength. The calibration curve was plotted 
using concentration against corrected absorbance. The optical parameters like, 
Sandell’s sensitivity, Molar absorptivity, correlation coefficient, slope, intercept, 
LOD, LOQ and Standard error were calculated for both the drugs. The correlation 
coefficient of the drug was found to be 0.999. This indicates that both the drugs obey 
Beer’s law and they were linear at the selected concentration range. The results are 
shown in Table 16.  
 For Quantification, the concentration of solution containing 10 µg mL-1 of 
Silodosin was prepared and measured at their respective wavelengths.  The amount of 
six test solutions was determined. The percentage purity of capsules was found to be 
98.35 ± 1.78, respectively. The amount present in capsules was in good concord with 
the label claim and the % RSD values were found to be 1.81, respectively. The results 
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of analysis are shown in Table-17. The low % RSD values indicate that the method 
has good precision.  
Further, the precision of the method was confirmed by Intra-day and Inter day 
analysis. The analysis of capsules was carried out for three times in the same day and 
one time in the three consecutive days. The % RSD value of Intra-day and Inter day 
analysis are 1.1066 and 0.7830, respectively. The results of analysis are shown in 
Table 18 and 19. Hence the precision was confirmed.   
The accuracy of the method was performed by recovery studies. To the 50% 
preanalysed formulation, a known quantity of Silodosin raw material solutions were 
added at three different concentration levels. The absorbance of the solutions was 
measured and the percentage recovery was calculated. The percentage recovery was 
found to be in the range of 78.75 – 81.07% .The average %RSD values of Silodosin 
was found to be 1.58, respectively. The low % RSD values of the drugs reveals that 
the method was more accurate. The recovery data was shown in Table 20. 
 5.4. VISIBLE SPECTROPHOTOMETRIC METHOD 
Silodosin has a secondary amine group which on treatment with MBTH 
reagent (3- Methyl 2-Benzthiazolinone Hydrazone Hydrochloride,) in presence of 
oxidizing agent gives a stable orange red coloured chromogen. The measurement of 
the intensity of coloured chromogen is the basis of this method. 
A solution of 10 µg mL-1 was prepared from the stock solution and added   
4 mL of ceric ammonium sulphate and 1 mL of 0.4% MBTH reagent and the solution 
was made up to the volume with 0.1 Hydrochloric acid. The intensity of the colored 
solution was scanned in the visible region of   400 - 800 nm. The spectrum was 
recorded. The recorded spectra showed that at 508 nm Silodosin has the maximum 
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absorbance. Hence this was selected as an analytical wavelength. This is shown in   
Figure 10. The optimization of the reagents were done by measuring the absorbance 
of drug solution by adding different volumes and different concentrations of ceric 
ammonium sulphate, different concentrations of MBTH reagent and different volumes 
of MBTH reagent.  Different aliquots of Silodosin were prepared in the concentration 
range of 10-50 µg mL-1. From the optimization finally 0.008% of 4 mL ceric 
ammonium sulphate (CAS) and 0.4% of 1 mL MBTH reagent were selected.  
The absorbances of solutions were measured at 508 nm. The calibration curve 
was plotted using concentration against absorbance. The preparation of calibration 
curve was repeated for six times. The optical characteristics like Correlation 
coefficient, Slope, Intercept, Molar absorptivity, Sandell’s sensitivity, LOD and LOQ 
were calculated. The correlation coefficient value for the calibration graph was found 
to be 0.999. This indicates that the drug obeys Beer’s law in the concentration range 
of 10- 50 µg mL-1. Hence the concentration was found to be linear. The calibration 
curve of Silodosin at 508 nm is shown in Figure 11. The optical characteristics are 
listed in Table 21. 
 The nominal concentration (30 µg mL-1) of Silodosin from the linearity was 
prepared and the absorbance of the solution was measured at 508 nm. The amount of 
test solution was calculated by using slope and intercept valves. This procedure was 
repeated for six times to ensure the precision of the method. The percentage label 
claim in capsule formulation was found to be 99.74 ± 0.6721. The amount present in 
capsule formulation was good concord with the label claim and the Percentage 
Relative Standard Deviation (% RSD) value was found to be 0.6750. The low % RSD 
value indicates that the method has good precision. The results of analysis are shown 
in Table 22. 
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The intermediate precision of the method was confirmed by Intraday and Inter 
day analysis. The analysis of formulation was repeated for three times in the same day 
and one time in the three successive days. The percentage RSD value for intraday and 
inter day analysis of Silodosin was found to be 0.9250 and 0.7106, respectively. The 
reports of analysis are shown in Tables 23 and 24, respectively. The results showed 
that the precision of the method was further confirmed.  
The developed method was validated for Ruggedness. In the present work, 
ruggedness was confirmed by different analysts and different instrument. The 
percentage RSD value for analyst 1 and analyst 2 was found to be 0.8462 and 0.8464, 
respectively. The % RSD value for instrument 1 was found to be and for instrument 2 
was found to be 0.8234 and 0.9514. The low % RSD values indicate that the method 
was more rugged. Reports of analysis are shown in Tables 25 and 26. 
The accuracy of the method was confirmed by recovery studies. To the 
preanalyzed formulation a known quantity of Silodosin raw material solution was 
added at three different concentrations. The absorbance of the solutions was measured 
and the percentage recovery was calculated.  The percentage recovery was found to be 
in the range of 100.32% to 100.83% of Silodosin. The % RSD values were found to be 
less than 2. The low % RSD values indicated that there is no interference due to 
excipients used in formulation during the analysis of Silodosin from capsule 
formulation. Hence the method was found to be accurate. The recovery data are shown 
in Table 27. 
5.5. RP-HPLC Method  
An exertion has been made to simple, precise, rapid, specific and accurate 
method for the estimation of Silodosin in pure form and in formulation by RP – 
HPLC method.   
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             The solution of 10 µg mL-1 of Silodosin in mobile phase (Acetonitrile: Buffer, 
 (1 mL triethylamine in 1000 mL water), pH 3 adjusted with orthophosphoric acid in 
the proportions of 22: 78% v/v) was prepared and the solution was scanned in the 
range of 200 – 400 nm. At 270 nm the drug showed maximum absorbance. Hence, 
270 nm was selected as detection wavelength for estimation of Silodosin by RP-HPLC 
method with isocratic elution technique and it was found that Silodosin was stable up 
to 3 hour 30 minutes. 
Based up on the properties of the drug the initial separation was achieved by 
using different mobile phase with different compositions. 
The mobile phase consists of Acetonitrile: Water (50: 50% v/v and 20: 80% 
v/v) was initially tried and chromatograms were recorded. These are shown in Figures 
12 and 13.  
 At 50: 50% v/v ratio, the drug was eluted with broad, and at 20: 80% v/v the 
peak for Silodosin was not proper because of more tailing. Hence water was replaced 
with methanol. In Acetonitrile: methanol (50: 50% v/v) composition a broad peak 
with slight tailing was observed with the retention time of less than 2 minutes. This is 
shown in Figure 14. 
 The different ratios of Acetonitrile: methanol was tried. But tailing of the peak 
cannot be modified. Hence it was planned to replace the water with Buffer: 1 mL 
triethylamine in 1000 mL water, pH 3 adjusted with orthophosphoric acid in the 
mixture of Acetonitrile: water as mobile phase. 
From the literature survey, pKa value for Silodosin was found to be 4.54. 
Based on this, the pH 3 was selected as mobile phase initially. The mobile phase 
consists of Acetonitrile: Buffer (1 mL triethylamine 1n 1000 mL water, pH 3 adjusted 
with orthophosphoric acid (50: 50% v/v) was tried. In this ratio a very broad peak was 
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observed. This is shown in Figure 15. Finally to get a sharp peak, Buffer composition 
was increased in the mobile phase. In the ratio of 22: 78% v/v, a sharp peak was 
observed as shown in Figure 16.  
After considering all system suitability parameters in different ratios, different 
pH and different flow rates the ratio of 22:78% v/v, with pH 3 and 1 mL/ min was 
selected as optimized mobile phase. The retention time of Silodosin in optimized 
chromatographic conditions was found to be 3.3 minutes. The system suitability 
parameters for optimized chromatogram are shown in Table 28.  
With the optimized chromatographic conditions, stock solutions of Silodosin 
were prepared by using methanol (for first dilution only) and mobile phase in the 
concentrations in the range of 56 – 104 µg mL-1. 20 µL of each solution were injected 
individually. The chromatograms were recorded at 270 nm. The chromatograms are 
shown in Figures 17 - 23. 
 The calibration curve was plotted using concentration against peak area. The 
procedure was repeated for three times.  The correlation co-efficient value was found 
to be 0.9998.The calibration graph is shown in Figure 24.The optical characteristics 
like correlation coefficient, slope, intercept, LOD, LOQ were calculated and are 
shown in Table 29. 
The capsule formulation (Silodal) was selected for the analysis. The nominal 
concentration (80 µg mL-1) from calibration curve was prepared in mobile phase.     
20 µL quantity of formulation was injected and the chromatogram was recorded. The 
precision of the method was confirmed by repeatability of formulation for three times 
in low level concentration, three times in middle level concentration, three times in 
high level concentration and chromatograms were recorded as shown in Figures 25-
33. The percentage purity of Silodosin present in formulation was found to be 99.47% 
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± 0.2442. The % RSD value was found to be 0.2457. It indicates that the method has 
good precision. The values are shown in table 30. 
The accuracy of the method was performed by recovery studies. To the 
preanalyzed formulation a known quantity of Silodosin raw material solution was 
added at three different concentrations (110 %, 120 % and 130 %) and solution were 
injected. The chromatograms were recorded and are shown in the Figures 34 - 36. 
The percentage recovery was found to be in the range of 99.78% to 100.08% of 
Silodosin. The % RSD values were found to be 0.1751 to 0.4419.   The Low % RSD 
values indicated that there are no interferences due to the excipients used in 
formulation during the analysis of Silodosin from capsule formulation. Hence the 
method was found to be accurate. The recovery data is shown in Table 31. 
The high percentage recovery revealed that no interference produced due to 
the excipients used in capsules. Therefore, the developed method was found to be 
more accurate. All the above parameters with the ease of operation ensure that the 
projected methods could be applied for the routine analysis of silodosin in pure form 
and in capsule dosage forms 
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6. SUMMARY AND CONCLUSION 
 
Two simple, rapid, precise and accurate UV - Visible spectrophotometric methods, 
Geometric method, Colorimetric and isocratic RP – HPLC methods were developed and 
validated for estimation of Silodosin in serum, pure form and in capsule dosage form. 
The methods employed for the analysis of Silodosin are 
I  UV spectroscopic method 
1. Simple UV method 
2. First Order Derivative method 
3. Geometric Correction method 
II Visible spectrophotometric method 
III RP – HPLC method 
6.1. UV SPECTROSCOPIC METHODS 
From the solubility profile methanol was chosen as a solvent for the estimation 
of Silodosin. The sample solution of 10 µg mL-1 of Silodosin in methanol was 
prepared and the solution was scanned in UV region in the wavelength range from 
200 to 400 nm by using methanol as blank. From the spectra, Silodosin shows 
maximum absorbance at 269.5 nm.   
          The percentage label claim present in capsule formulation was found to be 
100.37 ± 1.662%. The percentage recovery was found to be in the range of 99.4 – 
100.5%.  
         The same spectrum was derivatised and 230 nm selected for detection of 
Silodosin. The percentage label claim present in formulation was found to be 98.77 ± 
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0.7989 respectively. The percentage recovery was found to be in the range of 99.4 – 
100.73%. 
6.2. Geometric Correction Method 
 In Geometric Correction method, three wavelengths (257 nm, 269 nm and 284 
nm) were selected for the estimation of Silodosin in serum. The percentage label 
claim present in capsules was found to be 98.35 ± 1.78, respectively. The percentage 
recovery was found to be in the range of 78.75 – 81.07%. 
6.3. Visible Spectrophotometric Method  
  The sample of Silodosin treated with ceric ammonium sulphate and MBTH in 
0.1 M HCl (solution of 10 µg mL-1) was prepared and the solution was scanned in the 
wavelength range from 400 to 800 nm. From the spectra, Silodosin shows maximum 
absorbance at 508.0 nm. 
 The percentage label claim present in the capsule formulations was 
found to be 99.74 ± 0.6720. The % RSD value was found to be 0.6750. The low % 
RSD confirmed precision of the method. The percentage recovery was found to be in 
the range of 100.32% to 100.83% of Silodosin.                
6.4. RP – HPLC METHOD 
 In RP-HPLC method, mobile phase used is Acetonitrile: Buffer pH 3.0 (22:78 
V/V) with flow rate of 1.0 mL/min, the retention time of Silodosin was found to be 
3.19 at 270 nm. 
            The percentage purity was found to be 101.12 ± 0.810. The precision of the 
method was confirmed by repeatability of formulation for three times at three 
different concentrations. The accuracy of the method was confirmed by recovery 
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studies. The percentage recovery was found to be in the range between 99.95 – 100.70 
%. The low % RSD values for recovery indicated that the method was found to be 
accurate. 
Simple, rapid and accurate UV Spectroscopic (Simple UV method, First order 
derivative method, Geometric correction method), Colorimetric method and an 
isocratic RP –HPLC methods showed excellent sensitivity, reproducibility, accuracy, 
and repeatability, which is evidenced by low percentage relative standard deviation. 
The results obtained in recovery studies were indicating that there is no interference 
from the excipients used in the formulation.  By comparing above methods, UV - 
Visible spectrophotometric method was found to be economic when compared to RP - 
HPLC. Because the solvents and column used in RP - HPLC are very costly. When 
comparing the sensitivity of the methods, RP - HPLC method was found to be more 
sensitive than UV - Visible spectrophotometric method. Because the linearity range, 
LOD and LOQ were less in RP-HPLC method than UV-Spectrophotometric method. 
Hence it is suggested that the proposed UV Spectroscopic and an isocratic RP-HPLC 
methods can be effectively applied for the routine analysis of Silodosin in bulk and in 
capsule formulation. A simple, rapid and accurate Geometric correction method was 
developed which is used for quantitative estimation of Silodosin in biological sample.  
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FIGURE-1 
IR SPECTRUM OF SILODOSIN 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE-2 
 
UV- SPECTRUM OF SILODOSIN IN METHANOL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE-3 
 
 
CALIBRATION CURVE OF SILODOSIN 
BY UV-SPECTROSCOPIC METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE-4 
FIRST ORDER DERIVATIVE SPECTRUM OF 
SILODOSIN IN METHANOL AT 230 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE-5 
 
 
       CALIBRATION CURVE OF SILODOSIN IN METHANOL AT 230 nm 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE-6 
 
 
CALIBRATION CURVE OF SILODOSIN 
BY GEOMETRIC CORRECTION METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE-7 
 
SPECTRUM OF SILODOSIN WITH SERUM 
BY GEOMETRIC CORRECTION METHOD 
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SPECTRUM OF SILODOSIN WITHOUT SERUM 
BY GEOMETRIC CORRECTION METHOD 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE-9 
COMBINED SPECTRUM OF SILODOSIN BY 
GEOMETRIC CORRECTION METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE-10 
 
SPECTRUM OF SILODOSIN IN 0.1M HCL 
BY COLORIMETRIC METHOD 
 
 
 
 
                                                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          
 
 
 
 
 
  
                                                                          FIGURE-11 
 
 
CALIBRATION CURVE OF SILODOSIN 
BY COLORIMETRIC METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                  FIGURE-12 
 
OPTIMIZATION CHROMATOGRAM OF SILODOSIN USING  
ACETONITRILE: WATER (50:50% v/v) 
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OPTIMIZATION CHROMATOGRAM OF SILODOSIN USING  
ACETONITRILE: WATER (80:20% v/v) 
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OPTIMIZATION CHROMATOGRAM OF SILODOSIN USING  
ACETONITRILE: METHANOL (50:50% v/v) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIGURE – 15 
 
OPTIMIZATION CHROMATOGRAM OF SILODOSIN 
IN ACETONITRILE: BUFFER pH 3 (50:50% V/V) 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE – 16 
 
OPTIMIZATION CHROMATOGRAM OF SILODOSIN 
IN ACETONITRILE: BUFFER pH 3 (22:78% V/V) 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE – 17 
 
LINEARITY CHROMATOGRAM OF SILODOSIN (56 µg/ mL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE – 18 
 
LINEARITY CHROMATOGRAM OF SILODOSIN (64 µg/ mL) 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE – 19 
 
 
LINEARITY CHROMATOGRAM OF SILODOSIN (72 µg/ mL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE – 20 
 
 
LINEARITY CHROMATOGRAM OF SILODOSIN (80 µg/ mL) 
 
 
 
 
 
 
 
 
                                                            
 
 
 
 
 
 
  
FIGURE – 21 
 
 
LINEARITY CHROMATOGRAM OF SILODOSIN (88 µg/ mL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIGURE – 22 
 
 
 
LINEARITY CHROMATOGRAM OF SILODOSIN (96 µg/ mL) 
 
 
 
 
 
 
 
 
 
  
FIGURE – 23 
 
 
LINEARITY CHROMATOGRAM OF SILODOSIN (104 µg/ mL) 
 
 
 
 
 
 
  
 
 
 
 
 
  
FIGURE-24 
 
 
CALIBRATION CURVE OF SILODOSIN 
BY RP – HPLC METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE – 25 
 
CHROMATOGRAM FOR ANALYSIS OF  
FORMULATION – SILODAL REPEATABILITY – 1 
[LOW LEVEL] 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIGURE – 26 
 
CHROMATOGRAM FOR ANALYSIS OF  
FORMULATION – SILODAL REPEATABILITY – 2 
[LOW LEVEL] 
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CHROMATOGRAM FOR ANALYSIS OF  
FORMULATION – SILODAL REPEATABILITY – 3 
[LOW LEVEL] 
 
 
 
 
 
 
 
 
  
FIGURE – 28 
 
CHROMATOGRAM FOR ANALYSIS OF  
FORMULATION – SILODAL REPEATABILITY – 1 
[MIDDLE LEVEL] 
 
 
 
 
 
 
 
 
  
FIGURE – 29 
 
CHROMATOGRAM FOR ANALYSIS OF  
FORMULATION – SILODAL REPEATABILITY – 2 
[MIDDLE LEVEL] 
 
 
 
 
 
 
 
 
 
 
  
 
FIGURE – 30 
 
CHROMATOGRAM FOR ANALYSIS OF  
FORMULATION – SILODAL REPEATABILITY – 3 
[MIDDLE LEVEL] 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE – 31 
 
CHROMATOGRAM FOR ANALYSIS OF  
FORMULATION – SILODAL REPEATABILITY – 1 
[HIGH LEVEL] 
 
 
 
 
 
 
  
 
FIGURE – 32 
 
CHROMATOGRAM FOR ANALYSIS OF  
FORMULATION – SILODAL REPEATABILITY – 2 
[HIGH LEVEL] 
 
 
 
 
 
 
 
 
  
 
 
FIGURE – 33 
 
CHROMATOGRAM FOR ANALYSIS OF  
FORMULATION – SILODAL REPEATABILITY – 3 
[HIGH LEVEL] 
 
 
 
 
 
 
 
 
 
 
  
 
FIGURE-34 
 
CHROMATOGRAM FOR RECOVERY STUDIES (110 %) OF 
CAPSULES BY RP-HPLC METHOD 
 
 
 
 
 
 
 
 
  
 
 
FIGURE-35 
 
CHROMATOGRAM FOR RECOVERY STUDIES (120 %) OF 
CAPSULES BY RP-HPLC METHOD 
 
 
 
 
 
 
  
 
FIGURE-36 
 
CHROMATOGRAM FOR RECOVERY STUDIES (130 %) OF 
CAPSULES BY RP-HPLC METHOD 
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TABLE – 1 
 
SOLUBILITY PROFILE OF DEFERASIROX IN POLAR   AND 
                              NON-POLAR SOLVENTS 
S 
.No. 
SOLVENTS EXTENT OF 
SOLUBILITY 
CATEGORY 
1. Distilled water 10 mg of substance was not  
Soluble up to 100mL 
Practically 
insoluble 
2. 0.1M Hydrochloric acid 10 mg in 0.2 mL Soluble 
3 0.1M Sodium Hydroxide 10 mg in more than 10 mL Insoluble 
4 Methanol 10 mg in 0.01 mL Very soluble 
5 Ethanol 10 mg in 0.02 mL Freely soluble 
6 DMF 10 mg in 0.05 mL Freely soluble 
7 Acetone 10 mg in 0.03 mL Freely Soluble 
8 N-Butanol 10 mg in 0.2 mL Soluble 
9 Acetonitrile 10 mg in 0.01 mL Very Soluble 
10 N-Hexane 10 mg in more than 10 mL Insoluble 
11 Isopropyl alcohol 10 mg in More than 10 mL Insoluble 
12 Ethyl acetate 10 mg in 0.3 mL Soluble 
13 6% Glacial acetic acid 10 mg in 0.1 mL Soluble 
14 Dichloromethane 10 mg in more than 10 mL Insoluble 
15 Chloroform 10 mg in More than 10 mL Soluble 
16 Toluene 10 mg in more than 10 mL Insoluble 
17 Phosphate buffer (pH 
7.0) 
10 mg in more than 10 mL  Insoluble 
18 Acetate buffer    (pH 3.5) 10 mg in 0.04 mL Freely Soluble 
19 Phosphate  buffer (pH 
6.0) 
10 mg in more than 10 mL  Insoluble 
20 Phosphate buffer(pH 
8.0) 
10 mg in more than 10 Ml  Insoluble 
  
 
 
TABLE – 2 
 
OPTICAL CHARACTERISTICS OF SILODOSIN 
 BY U.V SPECTROPHOTOMETRIC METHOD 
 
PARAMETERS SILODOSIN* At 269.5 nm 
Beers law limit (µg/mL) 5 – 25 
Molar absorptivity  
(L mol-1 cm-1) 10194.8454 
Sandell’s Sensitivity  
(µg/cm2/0.001 A.U.) 0.05064002 
Correlation Coefficient (r) 0.9999 
Regression Equation 
(y=mx+c) y = 0.019766x + 0.0018944 
Slope (m) 0.0197669 
Intercept (c) 0.0018944 
LOD (µg/mL) 0.27895855 
LOQ (µg/mL) 0.84532896 
Standard Error  0.001578 
                    *Mean of six observations 
 
 
 
 
 
 
 
  
 
TABLE-3 
 
QUANTIFICATION OF SILODOSIN FORMULATION BY UV 
METHOD 
 
S.NO 
Labelled 
amount 
(mg cap-1) 
Amount 
found*(mg) 
Percentage 
obtained* 
Average S.D %RSD 
1. 
2. 
3. 
4. 
5. 
6. 
 
4 
4 
4 
4 
4 
4 
 
4.05 
3.92 
3.96 
4.06 
4.07 
4.02 
 
101.4 
98.11 
99.01 
101.5 
101.7 
100.5 
 
100.37 
 
1.662 
 
 
1.657 
 
 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE-4 
 
 
INTRADAY ANALYSIS OF FORMULATION – SILODAL 
                                                   BY UV METHOD 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Sample 
No 
Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
 
 
 
SIL 
 
 
 
 
 
 
 
 
1 
 
 
2 
 
 
3 
 
 
 
4 
 
 
4 
 
 
4 
 
 
 
4.04 
 
 
4.05 
 
 
4.07 
 
101.0 
 
 
101.25 
 
 
101.75 
 
 
 
101.33 
 
 
 
0.3818 
 
 
 
0.3768 
 
 
 
 
 
0.0424 
  
TABLE-5 
 
 
INTERDAY ANALYSIS OF FORMULATION - SILODAL 
BY UV METHOD 
 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Sample 
No 
Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
 
 
 
 
SIL 
 
 
 
 
 
 
 
 
1 
 
 
2 
 
 
3 
 
 
 
4 
 
 
4 
 
 
4 
 
 
 
3.92 
 
 
4.06 
 
 
4.05 
 
98.11 
 
 
101.5 
 
 
101.4 
 
 
 
 
100.33 
 
 
 
 
1.9289 
 
 
 
 
1.9225 
 
 
 
 
 
 
0.2143 
  
TABLE-6 
 
RUGGEDNESS STUDY BY UV METHOD 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Condition Labeled 
Amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
SIL Analyst 1 
4 
4 
4 
4 
4 
4 
3.97 
3.93 
4.04 
4.02 
3.98 
3.95 
99.32 
98.30 
101.0 
100.7 
99.70 
98.75 
 
 
 
99.62 
 
 
 
1.0605 
 
 
 
0.0684 
 
 
 
0.1182 
SIL Analyst 2 
4 
4 
4 
4 
4 
4 
3.92 
4.06 
4.05 
4.06 
3.99 
4.02 
98.11 
101.5 
101.4 
101.7 
99.75 
100.7 
 
 
 
100.52 
 
 
 
1.3827 
 
 
 
1.3755 
 
 
 
0.1536 
  
TABLE-7 
 
RUGGEDNESS STUDY BY UV METHOD 
 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Condition Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D %R.S.D S.E 
 
 
SIL 
 
 
Instrument 
1 
4 
4 
4 
4 
4 
4 
4.05 
3.92 
3.96 
4.06 
3.95 
3.99 
101.4 
98.11 
99.01 
101.5 
98.90 
99.91 
 
 
 
99.80 
 
 
 
1.3965 
 
 
 
1.3993 
 
 
 
0.0217 
 
 
 
SIL 
 
 
 
Instrument 
2 
4 
4 
4 
4 
4 
4 
3.92 
3.99 
4.05 
3.97 
3.95 
4.04 
98.11 
99.91 
101.4 
99.25 
98.75 
101.0 
 
 
 
99.73 
 
 
 
1.2844 
 
 
 
1.2878 
 
 
 
0.1427 
  
TABLE – 8 
 
 
RECOVERY ANALYSIS OF FORMULATION – SILODAL 
BY UV – METHOD 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
Drug Percentage 
Amount 
present 
(µg/mL) 
Amount 
added 
(µg/mL) 
Amount 
estimated 
(µg/mL)* 
Amount 
recovered 
(µg/mL)* 
% 
Recovery 
 
Average 
(%) 
±  
S.D 
% 
R.S.D 
 
S.E 
 
 
 
 
 
 
SIL 
 
 
80 
 
 
 
 
100 
 
 
 
 
 
120 
 
4.95 
4.95 
4.95 
 
    4.95 
4.95 
4.95 
 
    4.95 
4.95 
4.95 
 
 
 
8.0 
8.0 
8.0 
 
10.0 
10.0 
10.0 
 
12.0 
12.0 
12.0 
 
12.99 
13.01 
12.98 
 
15.003 
15.04 
15.03 
 
16.94 
16.83 
16.87 
 
8.04 
8.06 
8.03 
 
10.05 
10.09 
10.08 
 
11.99 
11.88 
11.92 
 
100.5 
100.7 
100.3 
 
100.5 
100.9 
100.8 
 
99.9 
99.0 
99.3 
 
100.5 
± 
0.2 
 
100.73 
± 
0.2081 
 
99.4 
± 
0.4582 
 
0.1990 
 
 
 
0.2066 
 
 
 
0.4610 
 
 
 
 
0.0222 
 
 
 
0.0231 
 
 
 
0.0509 
  
TABLE-9 
 
 
OPTICAL CHARACTERISTICS OF SILODOSIN 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD) 
 
 
 
PARAMETERS SILODOSIN* At 230.0 nm 
Beers law limit (µg/mL) 5 – 25 
Molar absorptivity  
(L mol-1 cm-1) 1093.422 
Sandell’s Sensitivity  
(µg/cm2/0.001 A.U.) 0.4812495 
Correlation Coefficient (r) 0.9998 
Regression Equation 
(y=mx+c) y = 0.002080x + 0.0002385 
Slope (m) 0.00208062 
Intercept (c) 0.00023854 
LOD (µg/mL) 0.25981724 
LOQ (µg/mL) 0.78732499 
Standard Error  0.000032792 
                    *Mean of six observations 
 
 
 
 
 
 
  
TABLE-10 
 
QUANTIFICATION OF SILODOSIN FORMULATION 
                           BY FIRST ORDER DERIVATIVE METHOD 
 
S.NO 
Labelled 
amount 
(mg cap-1) 
Amount 
found*(mg) 
Percentage 
obtained* 
Average S.D %RSD 
1. 
2. 
3. 
4. 
5. 
6. 
 
4 
4 
4 
4 
4 
4 
 
3.95 
3.92 
3.93 
3.99 
3.94 
3.98 
 
98.75 
98.00 
98.25 
99.91 
98.50 
99.50 
 
98.81 
 
0.7989 
 
 
0.8088 
 
 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE-11 
 
 
INTRADAY ANALYSIS OF FORMULATION - SILODAL 
BY FIRST ORDER DERIVATIVE METHOD 
 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Sample 
No 
Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
 
 
 
SIL 
 
 
 
 
 
 
 
 
1 
 
 
2 
 
 
3 
 
 
 
4 
 
 
4 
 
 
4 
 
 
 
3.96 
 
 
4.01 
 
 
4.05 
 
99.0 
 
 
100.25 
 
 
101.25 
 
 
 
100.91 
 
 
 
1.1273 
 
 
 
1.1254 
 
 
 
 
 
0.1252 
  
TABLE-12 
 
 
INTERDAY ANALYSIS OF FORMULATION - SILODAL 
BY FIRST ORDER DERIVATIVE METHOD 
 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Sample 
No 
Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
 
 
 
 
SIL 
 
 
 
 
 
 
 
 
1 
 
 
2 
 
 
3 
 
 
 
4 
 
 
4 
 
 
4 
 
 
 
3.98 
 
 
4.07 
 
 
3.93 
 
99.5 
 
 
101.75 
 
 
98.25 
 
 
 
 
99.83 
 
 
 
 
1.7736 
 
 
 
 
1.7766 
 
 
 
 
 
 
0.1970 
  
TABLE-13 
 
RUGGEDNESS STUDY BY FIRST DERIVATIVE METHOD 
 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Condition Labeled 
Amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
SIL Analyst 1 
4 
4 
4 
4 
4 
4 
3.97 
3.93 
4.04 
4.02 
3.98 
3.95 
99.32 
98.30 
101.0 
100.7 
99.70 
98.75 
 
 
 
99.62 
 
 
 
1.0605 
 
 
 
0.0684 
 
 
 
0.1182 
SIL Analyst 2 
4 
4 
4 
4 
4 
4 
3.92 
4.06 
4.05 
4.06 
3.99 
4.02 
98.11 
101.5 
101.4 
101.7 
99.75 
100.7 
 
 
 
100.52 
 
 
 
1.3827 
 
 
 
1.3755 
 
 
 
0.1536 
  
TABLE-14 
 
RUGGEDNESS STUDY BY FIRST ORDER DERIVATIVE 
METHOD 
 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
                                                    
 
Drug Condition Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D %R.S.D S.E 
 
 
SIL 
 
 
Instrument 
1 
4 
4 
4 
4 
4 
4 
4.09 
3.95 
3.93 
3.97 
4.02 
4.05 
102.25 
98.75 
98.25 
99.25 
100.5 
101.25 
 
 
 
100.04 
 
 
 
1.5525 
 
 
 
1.5519 
 
 
 
0.1725 
 
 
 
SIL 
 
 
 
Instrument 
2 
4 
4 
4 
4 
4 
4 
4.10 
4.02 
3.92 
3.99 
4.06 
4.01 
102.5 
100.5 
98.0 
99.75 
101.5 
100.25 
 
 
 
100.41 
 
 
 
1.5383 
 
 
 
1.5320 
 
 
 
0.1709 
  
TABLE-15 
 
 
                                RECOVERY STUDIES OF SILODOSIN  
                            BY FIRST ORDER DERIVATIVE METHOD 
 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
Drug Percentage 
Amount 
present 
(µg/mL) 
Amount 
added 
(µg/mL) 
Amount 
estimated 
(µg/mL)* 
Amount 
recovered 
(µg/mL)* 
% 
Recovery 
 
Average 
(%) 
±  
S.D 
% 
R.S.D 
 
S.E 
 
 
 
 
 
 
SIL 
 
 
80 
 
 
 
 
100 
 
 
 
 
 
120 
 
4.96 
4.96 
4.96 
 
    4.96 
4.96 
4.96 
 
    4.96 
4.96 
4.96 
 
 
 
8.0 
8.0 
8.0 
 
10.0 
10.0 
10.0 
 
12.0 
12.0 
12.0 
 
12.91 
13.10 
13.006 
 
15.02 
15.07 
14.97 
 
16.89 
16.99 
17.04 
 
7.95 
8.14 
8.04 
 
10.05 
10.11 
10.01 
 
11.93 
12.03 
12.08 
 
99.3 
101.75 
100.5 
 
100.6 
101.1 
100.1 
 
99.4 
100.2 
100.6 
 
100.5 
± 
1.2 
 
100.73 
± 
0.5 
 
99.4 
± 
0.6110 
 
0.1990 
 
 
 
0.4970 
 
 
 
0.6106 
 
 
 
 
0.0222 
 
 
 
0.0555 
 
 
 
0.0678 
  
 
TABLE-16 
 
 
OPTICAL CHARACTERISTICS OF SILODOSIN 
 BY GEOMETRIC CORRECTION METHOD 
 
 
 
PARAMETERS 
SILODOSIN* 
At 257 nm, 269.5 nm, 284 
nm 
Beers law limit (µg/mL) 5 – 25 
Correlation Coefficient (r) 0.9934 
Regression Equation 
(y=mx+c) 
          y = 6.574145x + 
24.4141 
Slope (m) 6.574145 
Intercept (c) 24.4141 
LOD (µg/mL) 1.870081 
LOQ (µg/mL) 5.66690 
Standard Error  0.14333 
                   *Mean of six observations 
 
 
 
 
 
 
 
 
 
  
                                                  TABLE-17 
 
                 QUANTIFICATION OF SILODOSIN FORMULATION  
BY GEOMETRICCORRECTION METHOD 
 
 
 
S.NO 
Labelled 
amount 
(mg cap-1) 
Amount 
found(mg)* 
Percentage 
obtained* 
Average S.D %RSD 
1. 
2. 
3. 
4. 
5. 
6. 
 
8 
8 
8 
8 
8 
8 
 
7.92 
8.06 
7.72 
7.68 
7.91 
7.92 
 
99.00 
100.8 
96.5 
96.03 
98.8 
99.0 
 
98.35 
 
1.78 
 
 
1.81 
 
 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE-18 
 
 
 
INTRADAY ANALYSIS OF FORMULATION - SILODAL 
BY GEOMETRIC CORRECTION METHOD 
 
 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
 
 
Drug Sample 
No 
Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
 
 
 
SIL 
 
 
 
 
 
 
 
 
1 
 
 
2 
 
 
3 
 
 
 
8 
 
 
8 
 
 
8 
 
 
 
7.92 
 
 
8.06 
 
 
7.91 
 
99.0 
 
 
100.8 
 
 
98.8 
 
 
 
99.53 
 
 
 
1.1015 
 
 
 
1.1066 
 
 
 
 
 
0.122 
  
TABLE-19 
 
 
INTERDAY ANALYSIS OF FORMULATION - SILODAL 
BY GEOMETRIC CORRECTION METHOD 
 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Sample 
No 
Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
 
 
 
SIL 
 
 
 
 
 
 
 
 
1 
 
 
2 
 
 
3 
 
 
 
8 
 
 
8 
 
 
8 
 
 
 
7.91 
 
 
8.01 
 
 
7.90 
 
98.8 
 
 
100.12 
 
 
98.75 
 
 
 
99.22 
 
 
 
0.7769 
 
 
 
0.7830 
 
 
 
 
 
0.0863 
  
TABLE-20 
RECOVERY STUDIES OF SILODOSIN 
BY GEOMETRIC CORRECTION METHOD 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Amount 
present 
(mcg mL-1) 
Amount 
added 
 (mcg mL-1) 
Amount 
estimated* 
(mcg mL-1) 
Amount 
recovered* 
(mcg mL-1) 
[n=3] 
% 
recovered 
S.D % 
RSD 
Std 
error 
SIL 
4.91 8.00 11.21 6.30 78.75 
1.26 1.58 0.14 4.91 10.00 12.86 7.95 79.05 
4.91 12.00 14.72 9.81 81.07 
  
TABLE-21 
 
 
OPTICAL CHARACTERISTICS OF SILODOSIN 
BY COLORIMETRIC METHOD 
 
PARAMETERS SILODOSIN* At 269.5 nm 
Beers law limit (µg/mL) 10– 50 
Molar absorptivity  
(L mol-1 cm-1) 4506.954 
Sandell’s Sensitivity  
(µg/cm2/0.001 A.U.) 0.0726880 
Correlation Coefficient (r) 0.999 
Regression Equation 
(y=mx+c) 
y = 0.0137344x + 
0.0157420 
Slope (m) 0.0137344 
Intercept (c) 0.0157420 
LOD (µg/mL) 0.10161318 
LOQ (µg/mL) 0.307918 
Standard Error  0.0001061 
                    *Mean of six observations 
              
 
 
 
 
 
 
  
TABLE-22 
 
QUANTIFICATION OF SILODOSIN FORMULATION 
BY COLORIMETRIC METHOD 
 
S.NO 
Labelled 
amount 
(mg cap-1) 
Amount 
found*(mg) 
Percentage 
obtained* 
Average S.D %RSD 
1. 
2. 
3. 
4. 
5. 
6. 
 
8 
8 
8 
8 
8 
8 
 
8.01 
7.98 
7.99 
7.86 
7.97 
7.99 
 
100.12 
99.75 
99.87 
98.25 
99.62 
99.87 
 
99.58 
 
0.6721 
 
 
0.6750 
 
 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE-23 
 
 
INTRADAY ANALYSIS OF FORMULATION - SILODAL 
BY COLORIMETRIC METHOD 
 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
 
 
 
SIL 
 
 
 
 
 
 
 
 
8 
 
 
8 
 
 
8 
 
 
 
7.95 
 
 
7.92 
 
 
8.06 
 
99.37 
 
 
99.0 
 
 
100.75 
 
 
 
99.70 
 
 
 
0.9222 
 
 
 
0.9250 
 
 
 
 
 
0.1024 
  
TABLE-24 
 
INTERDAY ANALYSIS OF FORMULATION - SILODAL 
BY COLORIMETRIC METHOD 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D % 
R.S.D 
S.E 
 
 
 
SIL 
 
 
 
 
 
 
 
 
8 
 
 
8 
 
 
8 
 
 
 
7.93 
 
 
8.04 
 
 
8.01 
 
99.12 
 
 
100.5 
 
 
100.1 
 
 
 
99.90 
 
 
 
0.7100 
 
 
 
0.7106 
 
 
 
 
 
0.0788 
  
TABLE-25 
 
RUGGEDNESS STUDY BY COLORIMETRIC METHOD 
 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Condition Labeled 
Amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D %R.S.D S.E 
SIL Analyst 1 
8 
8 
8 
8 
8 
8 
7.90 
8.02 
8.08 
7.94 
7.99 
8.05 
98.75 
100.25 
101.0 
99.25 
99.87 
100.62 
 
 
 
99.95 
 
 
 
0.8458 
 
 
 
0.8462 
 
 
 
0.0939 
SIL Analyst 2 
8 
8 
8 
8 
8 
8 
8.09 
8.01 
7.97 
7.89 
8.04 
7.99 
101.12 
100.12 
99.62 
98.62 
100.5 
99.87 
 
 
 
99.97 
 
 
 
0.8462 
 
 
 
0.8464 
 
 
 
0.0940 
  
TABLE-26 
 
RUGGEDNESS STUDY BY COLORIMETRIC METHOD 
 
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Condition Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D %R.S.D S.E 
 
 
SIL 
 
 
Instrument 
1 
8 
8 
8 
8 
8 
8 
8.08 
8.01 
7.91 
7.98 
8.01 
7.91 
101.0 
100.12 
98.87 
99.75 
100.12 
98.87 
 
 
 
99.78 
 
 
 
0.8217 
 
 
 
0.8234 
 
 
 
0.0913 
 
 
 
SIL 
 
 
 
Instrument 
2 
8 
8 
8 
8 
8 
8 
7.99 
8.10 
8.07 
7.96 
7.90 
7.95 
99.87 
101.25 
100.87 
99.5 
98.75 
99.37 
 
 
 
99.93 
 
 
 
0.9508 
 
 
 
0.9514 
 
 
 
0.1056 
  
TABLE-27 
 
 
                          RECOVERY STUDIES OF SILODOSIN  
                                BY COLORIMETRIC METHOD 
 
 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
 
Drug Percentage 
Amount 
present 
(µg/mL) 
Amount 
added 
(µg/mL) 
Amount 
estimated 
(µg/mL)* 
Amount 
recovered 
(µg/mL)* 
% 
Recovery 
 
Average 
(%) 
±  
S.D 
% 
R.S.D 
 
S.E 
 
 
 
 
 
 
SIL 
 
 
80 
 
 
 
 
100 
 
 
 
 
 
120 
 
29.95 
29.95 
29.95 
 
   29.95 
29.95 
29.95 
 
   29.95 
29.95 
29.95 
 
 
 
24.0 
24.0 
24.0 
 
30.0 
30.0 
30.0 
 
36.0 
36.0 
36.0 
 
54.11 
54.15 
54.20 
 
60.08 
60.02 
60.26 
 
66.06 
65.98 
66.16 
 
24.16 
24.2 
24.25 
 
30.13 
30.07 
30.31 
 
36.11 
36.03 
36.21 
 
100.66 
100.83 
101.0 
 
100.43 
100.23 
101.0 
 
100.30 
100.08 
100.58 
 
100.83 
± 
0.16 
 
100.55 
± 
0.39 
 
100.32 
± 
0.25 
 
0.1681 
 
 
 
0.3973 
 
 
 
0.2498 
 
 
 
 
0.0188 
 
 
 
0.0443 
 
 
 
0.0278 
  
TABLE – 28 
 
SYSTEM SUITABILITY PARAMETERS FOR THE OPTIMIZED 
CHROMATOGRAM BY RP – HPLC METHOD 
 
PARAMETERS SILODOSIN STANDARD LIMIT 
 
Retention time 
 
 
3.38 
 
 
Tailing factor 
 
 
0.93 
 
< 2 
 
Asymmetrical factor 
 
 
0.86 
 
< 2 
 
Theoretical plates 
 
 
3936 
 
>2000 
 
Capacity factor 
 
 
3.82 
 
>1 
 
Theoretical plate per unit 
length 
 
 
0.4252 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
TABLE-29 
 
 
OPTICAL CHARACTERISTICS OF SILODOSIN  
(BY RP-HPLC METHOD) 
 
 
 
PARAMETERS SILODOSIN* At 230.0 nm 
Beers law limit (µg/mL) 56– 104 
Wavelength 270 nm 
Correlation Coefficient (r) 0.9998 
Regression Equation 
(y=mx+c) y = 30516.9x –86986 
Slope (m) 30516.9 
Intercept (c) -86986 
LOD (µg/mL) 0.24635 
LOQ (µg/mL) 0.74652 
Standard Error  9094.09 
                    *Mean of six observations 
 
 
 
 
 
 
 
 
  
TABLE-30 
 
QUANTIFICATION OF SILODAL FORMULATIONBY RP-HPLC 
 
 
Sample No 
 
Labeled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab) 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
Low Level -1 
Low Level -2 
Low Level-3 
 
Middle Level-1 
Middle Level-2 
Middle Level-3 
 
High Level-1 
High Level-2 
High Level-3 
 
 
8 
 
 
 
8 
 
 
        8 
 
   7.925 
7.963 
7.947 
 
7.953 
7.973 
7.969 
 
7.939 
7.957 
7.994 
    99.06 
99.54 
99.33 
 
99.41 
99.67 
99.61 
 
99.23 
99.46 
99.93 
  99.31 
 
 
 
99.56 
 
 
 
99.54 
 0.2406 
 
 
 
0.1361 
 
 
 
0.3561 
 
0.2422 
 
 
 
0.1367 
 
 
 
0.3584 
 
 
0.0267 
 
 
 
0.0151 
 
 
 
0.0396 
 
 
Average 7.958 99.47 99.47 0.2442 0.2457 0.0271 
 
 
 
 
 
 
 
 
  
 
                                                  TABLE-31 
 
 
              RECOVERY ANALYSIS OF FORMULATION - SILODAL 
                                           BY RP – HPLC METHOD 
 
 
      *Mean of three observations 
 
 
 
Drug Percentage 
Amount 
present 
(mg/mL) 
Amount 
added 
(mg/mL)* 
Amount 
estimated 
(mg/mL)* 
Amount 
recovered 
(mg/mL) 
% 
Recovery 
 
Average 
(%) 
±  
S.D 
% 
R.S.D 
 
S.E 
 
 
 
 
 
 
SIL 
 
 
110 
 
 
 
 
120 
 
 
 
 
 
130 
 
7.96 
7.96 
7.96 
 
7.96 
7.96 
7.96 
 
7.96 
7.96 
7.96 
 
0.8 
0.8 
0.8 
 
1.6 
1.6 
1.6 
 
2.4 
2.4 
2.4 
 
8.760 
8.751 
8.771 
 
9.555 
9.569 
9.546 
 
10.368 
10.354 
10.375 
 
0.80 
0.791 
0.811 
 
1.595 
1.609 
1.586 
 
2.408 
2.394 
2.415 
 
100.0 
98.87 
101.37 
 
99.68 
100.56 
99.12 
 
100.33 
99.75 
100.62 
 
100.08 
± 
1.2519 
 
99.78 
± 
0.7274 
 
100.23 
± 
0.4429 
 
0.2509 
 
 
 
0.1751 
 
 
 
0.4419 
 
 
 
 
0.1391 
 
 
 
0.0806 
 
 
 
0.0492 
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